Introduction {#s1}
============

Lifespan and maximum adult body size are fundamental life history traits that vary considerably between species ([@bib34]). The maximum lifespan among vertebrates, for example, ranges from over 211 years in the bowhead whale (*Balaena mysticetus*) to only 59 days in the pygmy goby (*Eviota sigillata*) whereas body sizes ranges from 136,000 kg in the blue whale (*Balaenoptera musculus*) to 0.5 g in the Eastern red-backed salamander (*Plethodon cinereus*) ([@bib34]). Similar to other life history traits, such as body size and metabolic rate or body size and age at maturation, body size and lifespan are strongly correlated such that larger species tend to live longer than smaller species ([Figure 1A](#fig1){ref-type="fig"}). While abiotic and biological factors have been proposed as major drivers of maximum body size evolution in animals, maximum body size within tetrapods appears to be largely determined by biology ([@bib76]; [@bib77]). Mammals, for example, likely share biological constraints on the evolution of very large body sizes with rare breaks in those constraints underlying the evolution of gigantism in some lineages ([@bib77]), such as Proboscideans (elephants and their and extinct relatives), Cetaceans (whales), and the extinct hornless rhinoceros *Paraceratherium* ('Walter').10.7554/eLife.11994.003Figure 1.Body size evolution in vertebrates.(**A**) Relationship between body mass (g) and lifespan (years) among 2556 vertebrates. Blue line shows the linear regression between log (body mass) and log (lifespan), R^2^ = 0.32. (**B**) Body size comparison between living (African and Asian elephants) and extinct (Steppe mammoth) Proboscideans, Cetaceans (Minke whale), and the extinct hornless rhinoceros *Paraceratherium* ('Walter'), and humans.**DOI:** [http://dx.doi.org/10.7554/eLife.11994.003](10.7554/eLife.11994.003)

A major constraint on the evolution of large body sizes in animals is an increased risk of developing cancer. If all cells have a similar risk of malignant transformation and equivalent cancer suppression mechanisms, organism with many cells should have a higher risk of developing cancer than organisms with fewer cells; Similarly organisms with long lifespans have more time to accumulate cancer-causing mutations than organisms with shorter lifespans and therefore should be at an increased risk of developing cancer, a risk that is compounded in large bodied, long-lived organisms ([@bib8]; [@bib10]; [@bib19]; [@bib64]; [@bib67]). There are no correlations, however, between body size and cancer risk or lifespan and cancer risk across species ([@bib46]), this lack of correlation is often referred to as 'Peto's Paradox' ([@bib10]; [@bib67]). Epidemiological studies in wild populations of Swedish roe deer (*Capreolus capreolus*) and beluga whales (*Delphinapterus leucas*) in the highly polluted St. Lawrence estuary, for example, found cancer accounted for only 2% ([@bib2]) and 27% ([@bib53]) of mortality, respectively, much lower than expected given body size of these species ([@bib10]).

Among the mechanisms large, long lived animals may have evolved that resolve Peto's paradox are a decrease in the copy number of oncogenes, an increase in the copy number of tumor suppressor genes ([@bib10]; [@bib46]; [@bib59]), reduced metabolic rates leading to decreased free radical production, reduced retroviral activity and load ([@bib39]), increased immune surveillance, and selection for \'cheater\' tumors that parasitize the growth of other tumors ([@bib58]), among many others. Naked mole rats (*Heterocephalus glaber*), for example, which have very long lifespans for a small-bodied organism evolved cells with extremely sensitive contact inhibition likely acting as a constraint on tumor growth and metastasis ([@bib74]; [@bib80]). Similarly long-lived blind mole rats (*Splanx sp*.) evolved an enhanced *TP53*-signaling and necrotic cell death mechanisms that also likely constrains tumor growth ([@bib4]; [@bib5]; [@bib6]; [@bib32]; [@bib52]). Thus, while some of the mechanisms that underlie cancer resistance in small, long-lived mammals have been identified, the mechanisms by which large bodied animals evolved enhanced cancer resistance are unknown.

Here we use evolutionary genomics and comparative cell biology to explore the mechanisms by which elephants, the largest extant land mammal ([Figure 1B](#fig1){ref-type="fig"}), have evolved enhanced resistance to cancer. We found that the elephant genome encodes a single *TP53* gene and 19 *TP53* retrogenes, several of which are transcribed and translated in elephant tissues. Comparison of the African and Asian elephant TP53 gene copy number with the copy number in the genome of the extinct American mastodon, woolly mammoth, and Columbian mammoth indicates that copy number increased relatively rapidly coincident with the evolution of large body-sizes in the Proboscidean lineage. Finally, we show that elephant cells have an enhanced response to DNA-damage that is mediated by a hyperactive TP53 signaling pathway and that this augmented TP53 signaling is dependent upon TP53 retrogenes and can be transferred to the cells of other species through exogenous expression of elephant TP53 retrogenes. These results suggest that the origin of large body sizes, long lifespans, and enhanced cancer resistance in the elephant lineage evolved at least in part through reinforcing the anti-cancer mechanisms of the major 'guardian of the genome' TP53.

Results {#s2}
=======

Expansion of the *TP53* repertoire in proboscideans {#s2-1}
---------------------------------------------------

We characterized *TP53* copy number in 61 Sarcopterygians (Lobe-finned fishes) with draft or completed genomes, including large, long-lived mammals such as the African elephant (*Loxodonta africana*), Bowhead (*Balaena mysticetus*) and Minke (*Balaenoptera acutorostrata scammoni*) whales. We found that all Sarcopterygian genomes encoded a single *TP53* gene and that some lineages also contained a few *TP53* retrogenes (*TP53RTG*), including marsupials, Yangochiropteran bats, and Glires, in which 'processed' *TP53* pseudogenes have previously been reported ([@bib14]; [@bib17]; [@bib36]; [@bib79]; [@bib85]; [@bib88]). We also identified a single *TP53RTG* gene in the lesser hedgehog tenrec (*Echinops telfairi*), which had been previously reported ([@bib7]), rock hyrax (*Procavia capensis*), and West Indian manatee (*Trichechus manatus*). The African elephant genome, however, encoded 19 TP53RTG genes ([Figure 2A](#fig2){ref-type="fig"}), 14 of which retain potential to encode truncated proteins ([Table 1](#tbl1){ref-type="table"}).10.7554/eLife.11994.004Figure 2.Expansion of the TP53RTG gene repertoire in Proboscideans.(**A**) TP53 copy number in 61 Sarcopterygian (Lobe-finned fish) genomes. Clade names are shown for lineages in which the genome encodes more than one TP53 gene or pseudogene. (**B**) Estimated *TP53/TP53RTG* copy number inferred from complete genome sequencing data (WGS, purple), 1:1 orthology (green), gene tree reconciliation (blue), and normalized read depth from genome sequencing data (red). Whiskers on normalized read depth copy number estimates show the 95% confidence interval of the estimate.**DOI:** [http://dx.doi.org/10.7554/eLife.11994.004](10.7554/eLife.11994.004)10.7554/eLife.11994.005Figure 2---figure supplement 1.Reconciled *TP53/TP53RTG* gene trees.Reconciled TP53RTG gene trees for Columbian mammoth, woolly mammoth, Asian elephant, and American mastodon.**DOI:** [http://dx.doi.org/10.7554/eLife.11994.005](10.7554/eLife.11994.005)10.7554/eLife.11994.006Table 1.Summary information for African elephant *TP53/TP53RTG* genes.**DOI:** [http://dx.doi.org/10.7554/eLife.11994.006](10.7554/eLife.11994.006)**Gene IdENSEMBL IdScaffold (loxAfr3)Chromosome (loxAfr4)Coding potentialORF sizeTP53**ENSLAFG0000000748347Chr 11Yes392aa**TP53RTG1**ENSLAFG00000025553175UnmappedNoN/A**TP53RTG2**N/A217UnmappedYes134aa**TP53RTG3**ENSLAFG00000027474406UnmappedYes79aa**TP53RTG4**N/A627UnmappedYes134aa**TP53RTG5**ENSLAFG00000027348221UnmappedYes162aa**TP53RTG6**N/A76Chr 27Yes123aa**TP53RTG7**N/A208UnmappedNoN/A**TP53RTG8**ENSLAFG00000027820294UnmappedYes210aa**TP53RTG9**ENSLAFG00000027669786UnmappedNoN/A**TP53RTG10**ENSLAFG00000030555221UnmappedYes210aa**TP53RTG11**N/A281Yes203aa**TP53RTG12**ENSLAFG00000028299825UnmappedYes180aa**TP53RTG13**ENSLAFG00000032042458UnmappedNoN/A**TP53RTG14**ENSLAFG00000026238928UnmappedYes210aa**TP53RTG15**ENSLAFG00000027365656UnmappedYes210aa**TP53RTG16**ENSLAFG00000030880378UnmappedNoN/A**TP53RTG17**ENSLAFG00000028692552UnmappedYes111aa**TP53RTG18**N/A498UnmappedYes111aa**TP53RTG19**ENSLAFG00000032258342UnmappedYes210aa

To trace the expansion of TP53RTG gene family in the Proboscidean lineage with greater phylogenetic resolution, we used three methods to estimate the minimum (1:1 orthology), average (normalized read depth), and maximum (gene tree reconciliation) *TP53/TP53RTG* copy number in the Asian elephant (*Elephas maximus*), extinct woolly (*Mammuthus primigenius*) and Columbian (*Mammuthus columbi*) mammoths, and the extinct American mastodon (*Mammut americanum*) using existing whole genome sequencing data ([@bib23], [@bib24]; [@bib71]; [@bib86]). As expected, we identified a single canonical TP53 gene in these species and estimated the *TP53RTG* copy number in the Asian elephant genome to be 12--17, approximately 14 in both the Columbian and woolly mammoth genomes, and 3--8 in the 50,000--130,000 year old American mastodon genome ([Figure 2B](#fig2){ref-type="fig"}and [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). These data indicate that large-scale expansion of the *TP53RTG* gene family occurred in the Proboscidean lineage and suggest that *TP53RTG* copy number was lower in ancient Proboscideans such as the mastodon, which diverged from the elephant lineage \~ 25 MYA ([@bib71]), than in recent species such as elephants and mammoths.

The *TP53RTG* repertoire expanded through repeated segmental duplications {#s2-2}
-------------------------------------------------------------------------

Several mechanisms may have increased the *TP53RTG* copy number in the Proboscidean lineage including serial retrotransposition from the *TP53* gene, serial retrotransposition from the *TP53* and one or more daughter transcribed retrogenes, repeated segmental duplications of chromosomal loci containing *TP53RTG* genes, or some combination of these mechanisms. Consistent with copy number expansion through a single retrotransposition event followed by repeated rounds of segmental duplication, we found that each *TP53RTG* retrogene was flanked by nearly identical clusters of transposable elements ([Figure 3A](#fig3){ref-type="fig"}) and embedded within a large genomic region with greater than 80% sequence similarity ([Figure 3B](#fig3){ref-type="fig"}). Next we used progressiveMAUVE to align the 18 elephant contigs containing *TP53RTG* retrogenes and found that they were all embedded within large locally collinear blocks that span nearly the entire length of some contigs ([Figure 3C](#fig3){ref-type="fig"}), as expected for segmental duplications.10.7554/eLife.11994.007Figure 3.TP53RTG copy number increased through segmental duplications.(**A**) Organization of the TP53 and TP53RTG loci in African elephant. The *TP53/TP53RTG* gene tree is shown at the left. The location of homologous transposable elements that flank the TP53RTG genes are shown and l Abegglen ed. TP53RTG genes with intact start codons are labeled with arrows, stop codons are shown in red. (**B**) Multiple sequence alignment (MUSCLE) of elephant TP53RTG containing contigs. The location of the TP53RTG genes is shown with a blue bar. Sites are color coded according to their conservation (see inset key). (**C**) ProgressiveMAUVE alignment of elephant TP53RTG containing contigs. Colored boxes shown the location of collinear blocks, lines connect homologous collinear blocks on different contigs.**DOI:** [http://dx.doi.org/10.7554/eLife.11994.007](10.7554/eLife.11994.007)

*TP53RTG* copy number expansion is correlated with proboscidean body size {#s2-3}
-------------------------------------------------------------------------

Our observation that *TP53RTG* genes expanded through segmental duplications suggests they may have a tree-like phylogenetic history that preserves information about when in the evolution of Proboscideans the duplicates occurred. Therefore we assembled a dataset of *TP53/TP53RTG* orthologs from 65 diverse mammals and jointly inferred the *TP53/TP53RTG* gene tree and duplication dates in a Bayesian framework to determine if *TP53/TP53RTG* copy number was correlated with body size evolution in Proboscideans. For comparison, we also inferred the phylogenetic history of *TP53/TP53RTG* genes using maximum likelihood and an additional Bayesian method. We found all phylogenetic inference methods inferred that the TP53RTG genes from elephant, hyrax, and manatee formed a well-supported sister clade to the canonical genes from these species, whereas the tenrec *TP53* and *TP53RTG* genes formed a separate well-supported clade ([Figure 4A](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). These data indicate that retrotransposition of *TP53* occurred independently in tenrecs and in the elephant, hyrax, and manatee stem-lineage (Paenungulata), followed by expansion of *TP53RTG* genes in the Proboscidean lineage.10.7554/eLife.11994.008Figure 4.TP53RTG copy number is correlated with body size evolution in Proboscideans.(**A**) Time calibrated Bayesian phylogeny of *TP53/TP53RTG* genes. *TP53RTG* genes are shown in blue, the 95% highest posterior density (HPD) of estimated divergence dates are shown as red bars, nodes with a posterior probability (PP)(PP) \> 0.95 are labeled with closed circles whereas nodes with a PP ≤ 0.95.95 are labeled with open circles. The period corresponding to the expansion of the *TP53RTG* gene repertoire is shown in a grey. (**B**) *TP53/TP53RTG* copy number (blue) and Proboscidean body size (red) increases through time are correlated.**DOI:** [http://dx.doi.org/10.7554/eLife.11994.008](10.7554/eLife.11994.008)10.7554/eLife.11994.009Figure 4---figure supplement 1.TP53/TP53RTG gene trees.Maximum likelihood gene trees with aBayes, Chi-Square, aLRT, and SH-like branch supports. Bayesian tree inferred by MrBayes. Numbers along branches indicate node supports from each method. Note that the full dataset included 65 diverse species and only the Paeunngulate clade is shown. TP53 gene trees were inferred using a general time reversible model (GTR), empirical nucleotide frequencies (+F), a proportion of invariable sites estimated from the data (+I), four gamma distributed rate categories (+G), and using the best of NNI and SPR branch moves during the topology search (for the maximum likelihood tree).**DOI:** [http://dx.doi.org/10.7554/eLife.11994.009](10.7554/eLife.11994.009)

Based on our time-calibrated phylogeny, we inferred that the initial retrotransposition of the TP53 gene in the Paenungulata stem-lineage occurred approximately 64 MYA (95% HPD = 62.3--66.2 MYA; [Figure 4A](#fig4){ref-type="fig"}). This was followed by a period of \~25 million years during which no further retrotranspositions or segmental duplications were fixed in the genome, however, the TP53RTG gene family rapidly expanded after \~40 MYA (95% HPD = 30.8--48.6 MYA; [Figure 4A](#fig4){ref-type="fig"}). To correlate *TP53/TP53RTG* copy number and the origin of large body sizes in Proboscideans we estimated *TP53/TP53RTG* copy number through time and gathered data on ancient Proboscidean body sizes from the literature ([@bib25]; [@bib76]). We found that the increase in *TP53/TP53RTG* copy number in the Proboscidean lineage and Proboscidean body size evolution closely mirrored each other ([Figure 4B](#fig4){ref-type="fig"}).

*TP53RTG12* is transcribed from a transposable element derived promoter {#s2-4}
-----------------------------------------------------------------------

If expansion of the *TP53RTG* gene repertoire played a role in the resolution of Peto's paradox during the evolution of large bodied Proboscideans, then one or more of the *TP53RTG* genes should be transcribed. Therefore we generated RNA-Seq data from Asian elephant dermal fibroblasts, African elephant term placental villus and adipose tissue, and used previously published RNA-Seq data from Asian elephant PBMCs ([@bib68]) and African elephant fibroblasts ([@bib16]) to determine if *TP53RTG* genes were transcribed. We found that the *TP53* and *TP53RTG12* genes were robustly transcribed in all samples, whereas *TP53RTG3* and *TP53RTG18* transcripts were much less abundant ([Figure 5A](#fig5){ref-type="fig"}). To confirm that the African and Asian elephant *TP53RTG* genes were transcribed, we designed a set of PCR primers specific to the *TP53* and *TP53RTG* genes that flank a diagnostic 15--30 bp deletion in *TP53RTG* genes ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}) and used RT-PCR to assay for expression in Elephant fibroblast cDNA generated from DNase treated RNA. Consistent with transcription of the *TP53RTG* genes, we amplified PCR products at the expected size for the *TP53* and *TP53RTG* transcripts but did not amplify PCR products from negative control (no reverse transcriptase) samples ([Figure 5B](#fig5){ref-type="fig"}). Sanger sequencing of the cloned PCR products confirmed transcription of *TP53RTG12* and *TP53RTG18/19* ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}) in African elephant and *TP53RTG12* and *TP53RTG13* in Asian elephant fibroblast. We note that we used a Poly-T primer for cDNA synthesis, thus the amplification of *TP53RTG* transcripts indicates that these transcripts are poly-adenylated.10.7554/eLife.11994.010Figure 5.TP53RTG12 is transcribed and translated.(**A**) Transcription of elephant *TP53* and *TP53RTG* genes in dermal fibroblasts, white adipose, and placental villi. RNA-Seq data are shown as mean transcripts per million (TPM) with 95% confidence intervals of TPM value. Blue bars show TPM estimates from 'end-to-end' read mapping and gray bars shown 'local' read mapping. (**B**) qRT-PCR products generated Asian (left, blue sqaure) and African (right, light blue square) elephant fibroblast cDNA using primers specific to TP53 and TP53RTG12. cDNA was generated from DNaseI-treated RNA. No reverse transcriptase (no RT) controls for each qPCR reaction are shown, end point PCR products are shown. (**C**) Coverage of mapped reads from Asian (dark blue) and African (light blue) elephant fibroblast RNA-Seq data across the region of scaffold_885 encoding the *TP53RTG12* gene. The location of TP53RTG12 exons predicted from geneid and GENESCAN are shown in blue introns are shown as lines with arrows indicating the direction of transcription. Gray bars show the location of transposable elements around the *TP53RTG12* gene, darker gray indicates high sequence similarity to the consensus of each element. PCR tiles across this region are shown for African (Lox.) and Asian (Ele.) elephants, PCR primers generating amplicons are shown in red. The inferred *TP53RTG12* transcript is shown below. one kb scale shown from position one of African elephant (Broad/loxAfr3) scaffold_825. (**D**) Relative luciferase (Luc.) expression in Asian and African fibroblasts transfected with either the promoterless pGL4.10\[*luc2*\] luciferase reporter vector (empty vector), pGL4.10 containing the RTE_LA consensus sequences (Consensus), pGL4.10 containing the RTE_LA from Asian elephant (Ele. RTE_LA), or pGL4.10 containing the RTE_LA from African elephant (Lox. RTE_LA). Results are shown as fold difference in Luc. expression standardized to empty vector and *Renilla* controls. n = 16, Wilcoxon P-values. (**E**) Western blot of total cell protein isolated from South African Rock hyrax, Asian elephant (*Elephas*), and African elephant (*Loxodona*) dermal fibroblasts. −, control cells. +, cells treated with 50 J/m^2^UV-C and the proteasome inhibitor MG-132. The name and predicted molecular weights of TP53 isoforms are shown.**DOI:** [http://dx.doi.org/10.7554/eLife.11994.010](10.7554/eLife.11994.010)10.7554/eLife.11994.011Figure 5---figure supplement 1.PCR and Sanger sequencing confirm *TP53RTG12* is transcribed in elephant fibroblasts.(**A**) Multiple sequence alignment (MSA) of African elephant *TP53* and *TP53RTG1-TP53RTG19*. Numbering (shown at top) is relative to the canonical TP53 transcript in African elephant (ENSLAFT00000007484), sequence conservation in this region is shown in Bits, as a logo, and percent identity (green, 100% identity of paralogs; yellow, \< 100% identity of paralogs). Bases in each gene are color-coded (blue, C; red, A; yellow, G; and T, green). The TP53RTG-specific deletion is shown as a black line, and the location of the PCR primers than span the deletion are shown as arrows. (**B**) Chromatogram from Sanger sequencing of the TP53RTG12 qRT-PCR amplicon confirm the *TP53RTG12* is transcribed in African elephant fibroblasts. Bases that flank the TP53RTG-specific deletion are highlighted in red. (**C**) Chromatogram from Sanger sequencing of the TP53RTG12 qRT-PCR amplicon confirm the *TP53RTG12* is transcribed in Asian elephant fibroblasts. Bases that flank the TP53RTG-specific deletion are highlighted in red.**DOI:** [http://dx.doi.org/10.7554/eLife.11994.011](10.7554/eLife.11994.011)10.7554/eLife.11994.012Figure 5---figure supplement 2.Unedited Western blots shown in [Figure 5E](#fig5){ref-type="fig"}.(**A**) Western blot of total cell protein isolated from African elephant and hyrax fibroblasts. −, control cells. +, cells treated with 50 J/m^2^UV-C and MG-132. 1° and 2°, probed with primary antibody against TP53 and secondary HRP conjugated antibody. 2° only, probed only with secondary HRP conjugated antibody (**B**) Western blot of total cell protein isolated from Asian elephant and hyrax fibroblasts. −, control cells. +, cells treated with 50 J/m^2^UV-C and MG-132. 1° and 2°, probed with primary antibody against TP53 and secondary HRP conjugated antibody. 2° only, probed only with secondary HRP conjugated antibody**DOI:** [http://dx.doi.org/10.7554/eLife.11994.012](10.7554/eLife.11994.012)

Most retrogenes lack native regulatory elements such as promoters and enhancers to initiate transcription, thus transcribed *TP53RTG* genes likely co-opted existing regulatory elements or evolved regulatory elements de novo. To identify putative transcriptional start sites and promoters of the highly expressed *TP53RTG12* gene we used geneid and GENESCAN to computationally predict exons in the African elephant gene and mapped the African and Asian elephant fibroblast RNA-Seq data onto scaffold_825, which encodes the *TP53RTG12* gene. We found that both computational methods predicted an exon \~2 kb upstream of the ENSEMBL annotated *TP53RTG12* gene, within an RTE-type non-LTR retrotransposon (RTE1_LA) that we annotated as Afrotherian-specific ([Figure 5C](#fig5){ref-type="fig"}). Consistent with this region encoding a transcribed 5'-UTR, a peak of reads mapped within the predicted 5'-exon and within the RTE1_LA retrotransposon ([Figure 5C](#fig5){ref-type="fig"}).

We attempted to identify the transcription start site of the *TP53RTG12* gene using several 5'-RACE methods, however, we were unsuccessful in generating PCR products from either African Elephant fibroblast or placenta cDNA, or Asian elephant fibroblast cDNA. Therefore, we designed a set of 34 PCR primers tiled across the region of scaffold_825 that encodes the *TP53RTG12* gene and used these primers to amplify PCR products from African and Asian Elephant fibroblast cDNA generated from DNase treated RNA. We then reconstructed the likely *TP53RTG12* promoter, transcription start site, and exon-intron structure from the pattern of positive PCR products. These data suggest that the major transcription initiation site of *TP53RTG12* is located within a RTE1_LA class transposable element ([Figure 5C](#fig5){ref-type="fig"}).

Next we tested the ability of the African and Asian elephant RTE1_LA elements and the RTE1_LA consensus sequence (as a proxy for the ancestral RTE1_LA sequence) to function as a promoter in transiently transfected African and Asian elephant fibroblasts when cloned into the promoterless pGL4.10\[*luc2*\] luciferase reporter vector. We found that the African and Asian elephant RTE1_LA elements increased luciferase expression 3.03-fold (t-test, p=2.41 × 10^--8^) and 1.37-fold (t-test, p=2.60 × 10^--4^), respectively, compared to empty vector controls ([Figure 5D](#fig5){ref-type="fig"}). However, luciferase expression from the pGL4.10\[*luc2*\] vector containing the RTE1_LA sequence was not significantly different than the empty vector control in either Asian (0.96-fold; t-test, p=0.61) or African elephant fibroblasts (0.95-fold; t-test, p=0.37; [Figure 5D](#fig5){ref-type="fig"}). These data indicate that transcription of TP53RTG12 likely initiates within a RTE1_LA-derived promoter, but that the ability of this RTE1_LA element to function as a promoter is not an ancestral feature of RTE1_LA elements.

Elephant cells likely express TP53RTG proteins and numerous isoforms of TP53 {#s2-5}
----------------------------------------------------------------------------

To determine if *TP53RTG* transcripts are translated, we treated African elephant, Asian elephant, and hyrax cells with 50 J/m^2^ UV-C (to stabilize TP53) and the proteasome inhibitor MG-132 (to block protein degradation), and assayed for TP53/TP53RTG proteins by Western blotting total cell protein with a polyclonal TP53 antibody (FL-393) that we demonstrated recognizes Myc-tagged TP53RTG12. We identified bands in both African and Asian elephant and hyrax total cell protein at the expected size for the full length p53, Δ133 p53β/γ, and p53ψ-like isoforms of the TP53 protein ([@bib40]) as well as high molecular weight bands corresponding to previously reported SDS denaturation resistant TP53 oligomers ([@bib15]; [@bib60]) and (poly)ubiquitinated TP53 congugates ([@bib78]) ([Figure 5E](#fig5){ref-type="fig"}). We also identified an elephant-specific band at the expected size for the TP53RTG12 (19.6 kDa) and TP53RTG19 (22.3 kDa) proteins, suggesting that the *TP53RTG12* and *TP53RTG19* transcripts are translated in elephant fibroblasts ([Figure 5E](#fig5){ref-type="fig"}and [Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}).

Elephant cells have an enhanced TP53-dependent DNA-damage response {#s2-6}
------------------------------------------------------------------

Our observation that *TP53RTG* genes are expressed suggests that elephant cells may have an altered TP53 signaling system compared to species without an expanded *TP53/TP53RTG* gene repertoire. To directly test this hypothesis we transiently transfected primary African elephant, Asian elephant, South African Rock hyrax (*Procavia capensis capensis*), East African aardvark (*Orycteropus afer lademanni*), and Southern Three-banded armadillo (*Tolypeutes matacus*) dermal fibroblasts with a luciferase reporter vector containing two TP53 response elements (pGL4.38\[*luc2p*/p53 RE/Hygro\]) and Renilla control vector (pGL4.74\[*hRluc*/TK\]). Next we used a dual luciferase reporter assay to measure the activation of the TP53 pathway in response to treatment with three DNA damage inducing agents (mitomycin C, doxorubicin, or UV-C) or nutlin-3a, which inhibits the interaction between MDM2 and TP53 and thus promotes TP53 signaling. We found that elephant cells generally up-regulated TP53 signaling in response to lower doses of each drug and UV-C than closely related species without an expanded TP53 gene repertoire ([Figure 6A](#fig6){ref-type="fig"}), indicating elephant cells have evolved an enhanced TP53 response.10.7554/eLife.11994.013Figure 6.Elephant cells have enhanced TP53 signaling and are hyper-responsive to DNA damage.(**A**) Relative luciferase (Luc.) expression in African elephant, Asian elephant, hyrax, aardvark, and armadillo fibroblasts transfected with the pGL4.38\[*luc2p*/p53 RE/Hygro\] reporter vector and treated with either mitomycin c, doxorubicin, nutlin-3a, or UV-C. Data are shown as fold difference in Luc. expression 18 hr after treatment standardized to species paired empty vector and *Renilla* controls. n = 12, mean±SD. (**B**) Relative capsase-3/7 (Cas3/7) activity in African elephant, Asian elephant, hyrax, aardvark, and armadillo treated with either mitomycin c, doxorubicin, nutlin-3a, or UV-C. Data are shown as fold difference in Cas3/7 activity 18 hr after treatment standardized to species paired untreated controls. n = 12, mean±SD.**DOI:** [http://dx.doi.org/10.7554/eLife.11994.013](10.7554/eLife.11994.013)

To determine the consequences of an enhanced TP53 response we treated primary African and Asian elephant, hyrax, aardvark, and armadillo dermal fibroblasts with mitomycin C, doxorubicin, nutlin-3a, or UV-C and measured cell viability (live-cell protease activity), cytotoxicity (dead-cell protease activity), and the induction apoptosis (caspase-3/7 activation) using an ApoTox-Glo Triplex assay. Consistent with the results from the luciferase assay, we found that lower doses of mitomycin C or doxorubicin induced apoptosis in elephant cells than the other species ([Figure 6B](#fig6){ref-type="fig"}) and that the magnitude of the response was greater in elephant than other species ([Figure 6A](#fig6){ref-type="fig"}). Similarly UV-C exposure generally induced more elephant cells to undergo apoptosis than other species ([Figure 6A](#fig6){ref-type="fig"}). A striking exception to this trend was the response of elephant cells to the MDM2 antagonist nutlin-3a, which elicited a strong TP53 transcriptional response ([Figure 6A](#fig6){ref-type="fig"}) but did not induce apoptosis ([Figure 6B](#fig6){ref-type="fig"}). Thus we conclude that elephant cells generally upregulate TP53 signaling and apoptosis at lower levels of DNA-damage than other species, but are resistant to nutlin 3 a induced apoptosis.

TP53RTG genes are required for enhanced TP53 signaling and DNA-damage responses {#s2-7}
-------------------------------------------------------------------------------

To test if *TP53RTG* genes are necessary for the enhanced TP53-dependent DNA-damage response, we cotransfected African elephant fibroblasts with the pGL4.38\[*luc2p*/p53 RE/Hygro\] luciferase reporter vector, the pGL4.74\[*hRluc*/TK\] Renilla control vector, and either a TP53RTG-specific siRNA or a scrambled siRNA control ([Figure 7A](#fig7){ref-type="fig"}). Next we used a dual luciferase reporter assay to measure the activation of the TP53 pathway in response to treatment mitomycin C, doxorubicin, UV-C, or nutlin-3a. As expected given our previous results, we found that African elephant fibroblasts transfected with control siRNA induced TP53 signaling in response to each treatment ([Figure 7A](#fig7){ref-type="fig"}). In contrast, African elephant fibroblasts transfected with *TP53RTG*-specific siRNA had significantly lower luciferase expression, and thus reduced TP53 signaling, in response to either DNA-damaging agents (mitomycin C, doxorubicin, UV-C) or MDM2 antagonism (nutlin-3a). *TP53RTG* knockdown also elevated baseline TP53 signaling ([Figure 7B](#fig7){ref-type="fig"}). These data suggest that TP53RTG proteins have at least two distinct functions, inhibiting TP53 signaling in the absence of inductive signals and potentiation of TP53 signaling after the induction of DNA damage.10.7554/eLife.11994.014Figure 7.TP53RTG genes are required for enhanced TP53 signaling and DNA-damage responses.(**A**) Expression of TP53RTG and TP53 transcripts in African elephant fibroblasts treated with an siRNA to knockdown the expression of TP53RTG genes (red) or a scrambled (Control) siRNA (blue). Results are shown as fold-change in TP53RTG and TP53 transcript abundance relative to transcript abundance in scrambled siRNA control cells. The TP53RTG siRNA efficiently reduces the expression of TP53RTG transcripts, but does not reduce the expression of TP53 transcripts. (**B**) Relative luciferase (Luc.) expression in African elephant fibroblasts transfected with the pGL4.38\[*luc2p*/p53 RE/Hygro\] reporter vector and treated with an siRNA to knockdown the expression of TP53RTG genes (red) or a scrambled (negative control) siRNA (blue), and treated with either mitomycin c, doxorubicin, nutlin-3a, or UV-C. Data is shown as fold difference in Luc. expression 18 hr after treatment standardized to *Renilla* controls and no treatment. n \> 4, mean±SD. \*\*, Wilcoxon p\>0.01. \*\*\*, Wilcoxon p\>0.001.**DOI:** [http://dx.doi.org/10.7554/eLife.11994.014](10.7554/eLife.11994.014)

TP53RTG12 enhances TP53 signaling and DNA-damage responses via a transdominant mechanism {#s2-8}
----------------------------------------------------------------------------------------

To test if TP53RTG12 is sufficient to mediate enhanced TP53 signaling and DNA-damage responses we synthesized the African elephant *TP53RTG12* gene (with mouse codon usage) and cloned it into the mammalian expression vector pcDNA3.1(+)/myc-His. We then transiently transfected mouse 3T3-L1 cells with the *TP53RTG12* pcDNA3.1(+)/myc-His expression vector and used the pGL4.38\[*luc2P*/p53 RE/Hygro\] reporter system and ApoToxGlo assays to monitor activation of the TP53 signaling pathway and the induction of apoptosis in response to treatment with mitomycin C, doxorubicin, nutlin-3a, or UV-C. We found that heterologous expression of TP53RTG12 in mouse 3T3-L1 cells dramatically augmented luciferase expression from the pGL4.38\[*luc2P*/p53 RE/Hygro\] reporter vector in response to each treatment ([Figure 8A](#fig8){ref-type="fig"}) compared to empty vector controls, consistent with a enhancement of the endogenous TP53 signaling pathway. Similarly, expression of TP53RTG12 significantly augmented the induction of apoptosis in response to each treatment although the effect sizes were modest ([Figure 8B](#fig8){ref-type="fig"}). These data indicate that TP53RTG12 acts via a trans-dominant mechanism to enhance the induction of apoptosis by endogenous TP53 and that TP53RTG12 is sufficient to recapitulate at least some of the enhanced sensitivity of elephant cells to DNA damage. Furthermore, our observation that transfection with the *TP53RTG12* pcDNA3.1(+)/myc-His expression vector augments TP53 signaling and apoptosis suggests that the TP53RTG12 protein rather than transcript is responsible for these effects because the *TP53RTG12* transgene was synthetized with mouse codon usage and is only 73% (394/535 nts) identical to the elephant *TP53RTG12* gene.10.7554/eLife.11994.015Figure 8.TP53RTG12 enhances TP53 signaling and DNA-damage responses.(**A**) Relative luciferase (Luc.) expression in mouse 3T3-L1 cells co-transfected with either the pGL4.38\[*luc2P*/p53 RE/Hygro\] Luc. reporter vector, *TP53RTG12* pcDNA3.1(+)/myc-His expression vector, or empty pcDNA3.1(+)/myc-His and treated with either mitomycin c, doxorubicin, nutlin-3a, or UV-C. Data is shown as fold difference in Luc. expression 18 hr after treatment standardized to cells transfected with only pGL4.38\[luc2P/p53 RE/Hygro\] and *Renilla* controls. n = 12, mean±SD. \*\*\*, Wilcoxon p\>0.001. (**B**) Relative capsase-3/7 (Cas3/7) activity in mouse 3T3-L1 cells transfected with either the *TP53RTG12* pcDNA3.1(+)/myc-His expression vector or empty pcDNA3.1(+)/myc-His and treated with either mitomycin c, doxorubicin, nutlin-3a, or UV-C. Data is shown as fold difference in Cas3/7 activity 18 hr after treatment standardized to mock transfected. n = 12, mean±SD. \*\*\*, Wilcoxon p\>0.001.**DOI:** [http://dx.doi.org/10.7554/eLife.11994.015](10.7554/eLife.11994.015)

TP53RTG proteins are unlikely to directly regulate TP53 target genes because they lack critical residues required for nuclear localization, tetramerization, and DNA-binding ([Figure 9A](#fig9){ref-type="fig"}). Previous studies, for example, have shown the TP53 mutants lacking the tetramerization domain and C-terminal tail are unable to bind DNA or transactivate luciferase expression from a reporter vector containing TP53 response elements ([@bib41]). Similarly the p53Ψ isoform, which is truncated in the middle of the DNA binding domain and lacks the nuclear localization signal and oligomerization domain, is unable to bind DNA and is transcriptionally inactive ([@bib75]). Unexpectedly, we found that the GFP-tagged TP53RTG12 protein was both cytoplasmic and nuclear localized in transfected African elephant fibroblasts ([Figure 9B](#fig9){ref-type="fig"}), suggesting it interacts with another nuclear localized protein to enter the nucleus. Despite relatively strong nuclear localization, however, cells co-transfected with the *TP53RTG12* pcDNA3.1(+)/myc-His expression vector and the pGL4.38\[*luc2P*/p53 RE/Hygro\] luciferase reporter vector did not have elevated luciferase expression compared to controls, suggesting that TP53RTG12 is transcriptionally inactive or requires a cofactor to regulate target genes ([Figure 9C](#fig9){ref-type="fig"}).10.7554/eLife.11994.016Figure 9.TP53RTG proteins are unlikely to directly regulate TP53 target genes.(**A**) Domain structure of TP53 and TP53RTG proteins. (**B**) Localization of TP53RTG12-GFP in African elephant fibroblasts. (**C**) Relative luciferase (Luc.) expression in African elephant fibroblasts transfected with co-transfected with either the *TP53RTG12* pcDNA3.1(+)/myc-His expression vector and the pGL4.38\[*luc2P*/p53 RE/Hygro\] luciferase reporter vector, or empty pcDNA3.1(+)/myc-His and the pGL4.38\[*luc2P*/p53 RE/Hygro\] luciferase reporter vector. Data are shown as fold difference in Luc. expression 48 hr after transfection standardized to *Renilla* and cells transfected with pcDNA3.1(+)/myc-His and pGL4.38\[*luc2P*/p53 RE/Hygro\]. n = 10.**DOI:** [http://dx.doi.org/10.7554/eLife.11994.016](10.7554/eLife.11994.016)

A model for TP53RTG function -- decoy or guardian? {#s2-9}
--------------------------------------------------

While TP53RTG12 does not appear to directly regulate gene expression, many of the TP53RTG proteins (including TP53RTG12) retain the MDM2 interaction motif in the transactivation domain and dimerization sites in the DNA binding domain ([Figure 9A](#fig9){ref-type="fig"}). These data suggest at least two non-exclusive models of TP53RTG action: (1) TP53RTG proteins may act as 'decoys' for the MDM2 complex allowing the canonical TP53 protein to escape negative regulation ([Figure 10A](#fig10){ref-type="fig"}); and (2) TP53RTG proteins may protect canonical TP53 from MDM2 mediated ubiqutination, which requires tetramerization ([@bib43]; [@bib51]), by dimerizing with canonical TP53 and thereby preventing the formation of tetramers ([Figure 10F](#fig10){ref-type="fig"}).10.7554/eLife.11994.017Figure 10.TP53RTG12 interacts with TP53 but not MDM2.(**A**) Decoy model of TP53RTG12 function. Under normal conditions TP53 is negatively regulated by the MDM complex which ubiquitinates TP53 tetramers leading to proteosomal degradation. Upon DNA damage TP53 is phosphorylated, preventing interaction with the MDM complex and activating downstream TP53 signaling. In elephant cells TP53RTG12 may dimerize with the MDM2 complex, allowing TP53 to escape negative regulation. (**B**) Logo of the MDM2 interaction motif from 99 mammalian TP53 proteins (upper) and TP53RTG proteins (lower). (**C**) Structure model of the MDM2/TP53 (left) and MDM2/TP53RTG12 (right) interaction. MDM2 is shown in tan with hydrophobic residues that mediate the interaction with TP53 as spheres, TP53 in gray with W23 as a sphere, and TP53RTG12 shown in blue with G23 as a sphere. (**D**) Predicted effects of the W23G substitution (ΔΔG) on the stability of the MDM2/TP53RTG12 interaction estimated with mCSM, SDM, and DUET. (**E**) HEK-293 cells were transiently transfected with the TP53RTG12 pcDNA3.1(+)/myc-His expression vector and total cell protein immunoprecipitated with an α-MDM2 antibody. Co-immunoprecipitation of Myc-tagged TP53RTG12 and TP53 were assayed by Western blotting with α-Myc, α-TP53, and α-MDM2 antibodies after chemically stripping the blot, respectively. Although TP53 was co-immunoprecipitated, Myc-tagged TP53RTG12 was not. (**F**) Rather than interfering with the interaction between the MDM complex and TP53 as in the 'Decoy" model, TP53RTG12 may dimerize with canonical TP53 and block formation of TP53 tetramers. These TP53RTG12/TP53 dimers cannot be ubiquitinated generating a pool of TP53 proteins to rapidly respond to lower levels or DNA damage and stress than other species. (**G**) Logo of the dimerization domain of TP53 from 99 mammals (upper) and TP53RTG proteins (lower). (**H**) Model of the TP53/TP53RTG12 interaction. Residues critical for dimerization are shown as spheres, note sites involved in dimerization are conserved in TP53RTG proteins. (**I**) Predicted effects of the W23G substitution (ΔΔG) on the stability of the MDM2/TP53RTG12 interaction estimated with mCSM, SDM, and DUET. (**J**) HEK-293 cells were transiently transfected with the TP53RTG12 pcDNA3.1(+)/myc-His expression vector and total cell protein immunoprecipitated with an α-Myc antibody. Co-immunoprecipitation of TP53 and MDM2 were assayed by serial Western blotting with α-Myc, α-TP53, and α-MDM2 antibodies after chemically stripping the blot, respectively.**DOI:** [http://dx.doi.org/10.7554/eLife.11994.017](10.7554/eLife.11994.017)10.7554/eLife.11994.018Figure 10---figure supplement 1.Uncropped Western blots shown in [Figure 8B](#fig8){ref-type="fig"}.HEK-293 cells were transiently transfected with the TP53RTG12 pcDNA3.1(+)/myc-His expression vector and total cell protein immunoprecipitated with either an α-Myc (IP: RTG12-Myc) or α-MDM2 (IP: MDM2) antibody. Co-immunoprecipitation of Myc-tagged TP53RTG12, TP53, or MDM2 were assayed by Western blotting with α-Myc, α-TP53, and α-MDM2 antibodies respectively.**DOI:** [http://dx.doi.org/10.7554/eLife.11994.018](10.7554/eLife.11994.018)

The decoy model depends on the ability of TP53RTG proteins to physically interact with MDM2. Previous crystallographic studies of the TP53/MDM2 interaction have shown that a trio of residues in TP53 (F19, W23, and L26) insert deeply into a hydrophobic cleft in MDM2, which stabilizes the interaction ([@bib44]). We identified a W23G substitution in all TP53RTG proteins at a site that is invariant for tryptophan in TP53 proteins including African and Asian elephant TP53 ([Figure 10B](#fig10){ref-type="fig"}), suggesting that TP53RTG proteins may be unable to physically interact with MDM2. To infer the structural and functional consequences of the TP53RTG W23G substitution we generated a homology model of the elephant TP53RTG12/MDM2 complex using I-TASSER/ModRefiner ([@bib73]; [@bib87]; [@bib89]) and the crystal structure of the MDM2/TP53 dimer as a template ([@bib44]). We found that the TP53RTG12 transactivation domain was inferred to be a short α-helix ([Figure 10C](#fig10){ref-type="fig"}) and was very similar to the template structure (RMSD: 1.756), however, the W23G substitution is predicted to abolish crucial hydrophobic interactions between the amphipathic α-helix of TP53 and the hydrophobic cleft MDM2. Indeed, three methods ([@bib65]) inferred that the W23G substitution is destabilizing on the TP53RTG12/MDM2 interaction (mCSM ΔΔG = −2.42, SDM ΔΔG = −5.46, DUET ΔΔG = −2.38) ([Figure 10D](#fig10){ref-type="fig"}). To experimentally test for an interaction between TP53RTG12 and MDM2 we transiently transfected HEK-293 cells with the TP53RTG12 pcDNA3.1(+)/myc-His expression vector, immunoprecipitated endogenous human MDM2, and assayed for co-immunoprecipitation of TP53RTG12 by Western blotting. While we efficiently co-immunoprecipitated endogenous human TP53 we did not co-immunoprecipitate Myc-tagged TP53RTG12 ([Figure 10E](#fig10){ref-type="fig"}and [Figure 10---figure supplement 1](#fig10s1){ref-type="fig"}), consistent with a lack of interaction between TP53RTG12 and MDM2.

Unlike the decoy model, the guardian model of TP53RTG function depends upon a physical interaction between TP53RTG and TP53. The TP53 dimer is stabilized by hydrophobic and polar interactions including a shell of nonpolar interactions formed by P177, H178, M243, and G244 and a stabilization network next to the nonpolar layer formed by charged residues from the two monomers (R181, E180, and R174). In addition, several polar and charged residues nearby but not within the dimerization interface contribute to the stability of the interacting monomers including D184 with R175, most of which are conserved in TP53RTG proteins ([Figure 10G](#fig10){ref-type="fig"}). To infer if derived residues in the TP53RTG12 dimerization interface might disrupt a physical interaction between TP53RTG12 and TP53 we generated a homology model of the TP53RTG12/TP53 dimer using I-TASSER/ModRefiner ([@bib73]; [@bib87]; [@bib89]) and the crystal structure of the TP53 tetramer as a template ([@bib42]). We found that the TP53RTG12 dimerization interface was inferred to be a 2--4 residue α-helix ([Figure 10H](#fig10){ref-type="fig"}) that was nearly identical to the template structure (RMSD: 0.605), suggesting TP53RTG12-specific residues in dimerization interface are unlikely to disrupt the structure of the interface. Unlike the MDM2 interaction site, TP53RTG12-specific substitutions were predicted to maintain intermolecular hydrophobic interactions with TP53 ([Figure 10H](#fig10){ref-type="fig"}). Consistent with maintenance of dimerization potential, the net ΔΔG of the derived amino acid substitutions in the TP53RTG12 dimerization interface were under 2 ([Figure 10I](#fig10){ref-type="fig"}). To experimentally test for an interaction between TP53RTG12 and TP53 we transiently transfected HEK-293 cells with the TP53RTG12 pcDNA3.1(+)/myc-His expression vector, immunoprecipitated TP53RTG12 with a Myc antibody, and assayed for co-immunoprecipitation of endogenous human TP53 by Western blotting. We found that Myc-tagged TP53RTG12 efficiently co-immunoprecipitated endogenous human TP53 ([Figure 10J](#fig10){ref-type="fig"}). These data are consistent with a physical interaction between TP53RTG12 and TP53 but not between TP53RTG12 and MDM2, supporting the guardian model.

Discussion {#s3}
==========

A major developmental and life history constraint on the evolution of large body sizes and long lifespans in animals is an increased risk of developing cancer. There is no correlation, however, between body size or lifespan and cancer risk because large and long-lived organisms have evolved enhanced cancer suppression mechanisms that delay the development of cancer until post-reproduction (when selection generally cannot act). This simple evolutionary rational demands mechanistic explanations ([@bib64]), which have thus far been elusive. Here we show that the master tumor suppressor TP53, which is essential for preventing cancer because it triggers proliferative arrest and apoptosis in response to a variety of stresses such as DNA damage, was retroduplicated in the Paenungulate stem-lineage and rapidly increased in copy number through repeated segmental duplications during with the evolution of Proboscideans. The expansion of the *TP53RTG* gene family occurred coincident with the evolution of large body sizes and enhanced sensitivity of elephant cells to genotoxic stress, suggesting that Proboscideans resolved Peto's paradox at least in part through the evolution of augmented TP53 signaling.

Comparison to previous studies of elephant TP53 {#s3-1}
-----------------------------------------------

Previous studies have suggested that the *TP53* gene family expanded in the elephant lineage ([@bib1]; [@bib10]; [@bib11]), however, these studies did not establish the mechanism by which the *TP52RTG* gene family expanded. Several potential mechanisms could have increased *TP52RTG* copy number, including serial (independent) retrotranspostion from the parent *TP53* gene, a single retrotranspostion event followed by repeated rounds of segmental duplication of *TP52RTG* containing loci, retrotransposition of expressed *TP52RTG* genes, or some combination of these models. Each model is associated with a distinct set of genomic 'fingerprints'. If copy number expanded through independent retrotransposition events, for example, *TP53RTG* encoding regions of the genome will not be homologous whereas the model of a single retrotranspostion event followed by repeated rounds of segmental duplication predicts that the TP53RTG encoding loci will be homolgous. Consistent with copy number expansion through a single retrotransposition event followed by repeated rounds of segmental duplication, we found that flaking regions of each *TP52RTG* locus were homologous and contained the same unique combination of transposable elements. Indeed, the 3'-end of each duplicate terminates at a \~5 kb long L1MB5 LINE element suggesting that transposable element mediated recombination may have played a role in promoting segmental duplication.

If *TP53RTG* copy number expansion played a causal role in evolution of enhanced cancer resistance in elephants then the gene family must have expanded prior to or coincident with the evolution of increased body sizes in Proboscideans rather than after the evolution of large bodies but before the African and Asian elephant lineages diverged \~8 MYA ([@bib71], [@bib70]). Thus dating the expansion of the *TP53RTG* gene family is essential for determining if *TP53RTG* genes played a role in the evolution of enhanced cancer resistance in elephants. Previous studies, however, did not establish when *TP53RTG* copy number expanded in the evolution of Proboscideans. Fortunately our observation that copy number expansion occurred through segmental duplications allowed us to use molecular phylogenetic methods to date each duplication event. These data indicate that the initial *TP53RTG* retrotransposition event occurred in the Paenungulate stem-lineage \~ 64 MYA, followed the rapid expansion after \~40 MYA. We also found that the increase in *TP53RTG* copy number occurred coincident with the evolution of large bodies in the Proboscidean lineage, implicating copy number expansion in the resolution of Peto's paradox.

While [@bib1] found that elephant and human cells had different sensitivities to ionizing radiation, their taxon sampling did not allow for polarizing which species was different. Indeed, their taxon sampling does not allow for a Eutherian out-group. To determine if elephants have a derived sensitivity to genotoxic stress, we compared the response of fibroblasts from an African savannah elephant, an Asian elephant, and closely related out-group species to DNA damage inducing agents. Our out-group species included the South African Rock hyrax, the closest living relative of elephants, the East African aardvark, an Afrotherian from the sister lineage of the Paenungulates, and the Southern Three-banded armadillo, an Atlantogenatan from the sister lineage of the Afrotherians. Our results indicate that elephant cells are particularly sensitive to genotoxic tress, suggesting that this sensitivity evolved coincident with the evolution of large body sizes and an expanded *TP53* gene repertoire in Proboscideans.

An embarrassment of riches? {#s3-2}
---------------------------

Our observation that the elephant genome contains 19 *TP53RTG* genes raises numerous questions: Do these loci, for example, encode functional genes or pseudogenes and what processes underlie copy number expansion? Answers to these questions are essential for understanding whether *TP53RTG* genes are casually related to the resolution of Peto's paradox in Proboscideans or if they are irrelevant relicts of ancient transposition events, like so many other pseudogenes that riddle mammalian genomes. Unfortunately, it is difficult to answer these questions.

Which *TP53RTG* loci encode functional genes and which encode pseudogenes is not easy to infer. Many duplicate genes are preserved because they evolve tissue-specific or developmental-stage specific expression patterns (subfunctionalization), new functions (neofunctionalization) that resolve redundancy between duplicates, or reduced expression levels that preserves correct expression dosage. Exhaustively characterizing gene expression in elephant tissues is difficult because appropriate tissue samples are unavailable, therefore we are unable to definitively determine which *TP53RTG* loci are transcribed. Our RNA-Seq and RT-PCR/Sanger sequencing data indicate that at least *TP53RTG12*, *TP53RTG18/19*, and *TP53RTG13* are transcribed in dermal fibroblasts. [@bib1] used RT-PCR and Sanger sequencing to show two distinct transcripts were expressed in elephant PBMCs, but they did not assign the loci to which these transcripts correspond. We analyzed the chromatograms shown in Abegglen et al. Figure 4 and found that the 185 bp product is likely a transcript from the *TP553RTG14* gene and the 201 bp product is likely a transcript from the *TP553RTG5* gene. Thus, our combined data suggest that at least five *TP53RTG* genes are transcribed. Furthermore we did not observe *TP553RTG14* or *TP553RTG5* expression in adipose, placenta, or fibroblasts suggesting that the expression of some *TP53RTG* genes is tissue-specific.

The large number of *TP53RTG* loci in elephants combined with the observation that only five are transcribed suggests that this gene family may evolve by a birth and death process, in which new genes are created by duplication and some duplicates are maintained in the genome whereas others become nonfunctional or deleted similar to other large genes families such as histones ([@bib31]; [@bib72]) and venom genes ([@bib49]). Under this model selection acts to maintain a minimal number of functional copies (functional copy number) rather than total copy number, the increase in total copy number is driven by the total number of loci and the rates of duplication, loss, and fixation. Thus the overall increase in total *TP53RTG* copy number may be a selectively neutral process, driven simply by higher rates of duplication and/or fixation than loss.

Is TP53RTG12 a decoy, a guardian, or something else? {#s3-3}
----------------------------------------------------

Our results demonstrate that elephant cells induce TP53 signaling and trigger apoptosis at lower thresholds of genotoxic stress than closely related species without an expanded *TP53* repertoire and that this reduced sensitivity is dependent upon *TP53RTG* genes. Furthermore, heterologous expression of TP53RTG12 in mouse cells was sufficient to augment endogenous TP53 signaling and recapitulate an elephant-like sensitivity to genotoxic stress, indicating that TP53RTGs acts through a transdominant mechanism. While the mechanism of action is unclear, *TP53RTG* genes may augment TP53 signaling through several non-exclusive mechanisms including functioning as non-coding RNAs ([@bib66]), protein 'decoys' for the MDM2 complex that allowing canonical TP53 to escape negative regulation ([@bib1]), and protein 'guardians' that protect canonical TP53 from MDM2 mediated ubiqutination.

Consistent with the guardian model, we found that Myc-tagged TP53RTG12 efficiently co-immunoprecipitated with endogenous TP53 but not with endogenous MDM2. The lack of an interaction between TP53RTG12 and MDM2 likely results from a W23G substitution that is predicted to abolish a crucial hydrophobic interaction between the amphipathic α-helix of TP53 and the hydrophobic cleft MDM2. The W23G substitution is found in all TP53RTG proteins but not African and Asian elephant TP53, indicating that it occurred before the expansion of the *TP53RTG* gene family and likely prevents interaction of any TP53RTG protein and MDM2. Previous studies have shown that tetramerization of TP53 is required for its efficient MDM2-mediated ubiquitination ([@bib43]; [@bib51]), suggesting that TP53RTG proteins may dimerize with and protect TP53 from ubiquitination thereby contributing to a standing pool of TP53 that is able to rapidly respond to DNA damage. Consistent with this mechanism, transgenic mice with an increase in TP53 copy number ([@bib28]) or a hypomorphic *Mdm2* allele have elevated basal TP53 activity and are resistant to tumor formation ([@bib55]), indicating that shifting the TP53-MDM2 equilibrium away from TP53 degradation can directly promote cancer resistance.

The 'decoy' model ([@bib1]) has also been challenged because it would allow for activation of the TP53 signaling pathway in the absence of DNA damage ([@bib63]), which is generally lethal in animal models ([@bib35]; [@bib48]). Thus if TP53RTG proteins allow TP53 to escape negative regulation by MDM2, how do elephants tolerate elevated basal TP53 levels? Clearly further studies are required to specifically test whether TP53RTG proteins interfere with the interaction between the MDM2 complex and TP53, protect TP53 from ubiquitination, or have other functions.

What do extra *TP53* genes cost? {#s3-4}
--------------------------------

Our observation reveals that functional *TP53* duplicates only occur in the elephant lineage (and perhaps some bats) suggests that increased *TP53* dosage has a cost. Previous studies found that transgenic mice that overexpress *Trp53* were cancer resistant but had major life history tradeoffs including slower pre- and post-natal growth rates and reduced size ([@bib50]), a shortened lifespan ([@bib50]), accelerated aging ([@bib82]), and reduced fertility ([@bib3]; [@bib50]), as well as developmental tradeoffs including reduced proliferation, cellularity, and atrophy across multiple organ and tissue systems ([@bib21]; [@bib50]), defective ureteric bud differentiation, and small kidneys ([@bib30]). Thus, increases in TP53 copy number protects against cancer but appears to come with the cost of developmental delays, accelerated aging, and reduced fertility ([@bib9]; [@bib20]; [@bib26]; [@bib69]).

Reduced male fertility appears to be a particularly expensive cost of increased *TP53* dosage. [@bib3]), for example, generated transgenic lines of mice with one (MTp53-176), two (MTp53-112), or 15 (MTp53-94) extra copies of the Trp53 gene fused to the inducible promoter of the metallothionein I (MT) gene. They found that transgenic males with the highest Trp53 dosage were nearly infertile because the majority of developing spermatids underwent apoptosis before developing into mature sperm, males with intermediate dosage were subfertile and produced sperm with abnormal morphologies (teratozoospermia) indicative of defective terminal differentiation of postmeiotic cells, whereas males with the lowest dosage were fertile. Similarly, [@bib50] generated a transgenic line that overexpresses the p44 isoform of *Trp53* (Δ40 p53) and found that both males and females exhibited shortened reproductive lifespans. Males, however, were more severely affected than females with a catastrophic loss of sperm-producing cells and massive degeneration of the seminiferous epithelium leading to a \'Sertoli-cell only\' phenotype.

In contrast to transgenic mice that either overexpress full length TP53 or the Δ40 p53 isoform, transgenic \'super p53\' mice with one (p53-tg) or two (p53-tg^b^) additional copies of the endogenous TP53 locus have an enhanced DNA-damage response and are tumor resistant, yet age normally and are fertile ([@bib28], [@bib29]; [@bib54]). Enhanced tumor suppression and normal aging is also observed in *Mdm2^puro/Δ7--12^* transgenic mice, which have one hypomorphic and one null allele of *Mdm2*, express ∼30% of the wild-type level of Mdm2, and have constitutively high TP53 activity ([@bib55], [@bib56]). These results suggest that the costs of increased *TP53* copy number are incurred above a threshold of about 2--3 extra copies and can be reduced by maintaining normal regulation of *TP53* transcription and negative post-transcriptional regulation by MDM2. Consistent with this model, deletion of either *Mdm2* or *Mdm4* rescues *Trp53*-dependent embryonic lethality in mice ([@bib27]; [@bib57]; [@bib61]) and zebrafish ([@bib13]).

Collectively, these data indicate that increased *TP53* dosage comes with a cost, and suggest that Proboscideans evolved a mechanism that reduced this cost, broke a major developmental and evolutionary constraint on *TP53* copy number, or perhaps evaded paying the cost of increased *TP53* copy number altogether. *TP53RTG* genes, for example, are transcribed from a transposable element derived promoter that is evolutionarily younger than the retrogenes. Thus, the initial TP53RTG genes were unlikely to be transcribed and incur a cost. Similarly, our phylogenetic analyses indicates that copy number expanded after the initial *TP53RTG* gene acquired several mutations, including a premature stop codon that terminates the protein before the DNA-binding domain, which likely reduces or completely eliminates the costs associated with TP53 target gene regulation. Although more detailed evolutionary and comparative analyses are required to determine if *TP53RTG* genes incurred a cost, it is possible that the costs were minimized because functional *TP53RTG* genes evolved through non-functional intermediates, which accumulated loss of function mutations that minimized redundancy with *TP53*.

Materials and methods {#s4}
=====================

Identification of *TP53/PT53RTG* genes in sarcopterygian genomes {#s4-1}
----------------------------------------------------------------

We used BLAT to search for *TP53* genes in 61 Sarcopterygian genomes using the human TP53 protein sequences as an initial query. After identifying the canonical *TP53* gene from each species, we used the nucleotide sequences corresponding to this *TP53* CDS as the query sequence for additional BLAT searches within that species genome. To further confirm the orthology of each *TP53* gene we used a reciprocal best BLAT approach, sequentially using the putative CDS of each *TP53* gene as a query against the human genome; in each case the query gene was identified as TP53. Finally, we used the putative amino acid sequence of the TP53 protein as a query sequence in a BLAT search.

We thus used BLAT to characterize the *TP53* copy number in Human (*Homo sapiens*; GRCh37/hg19), Chimp (*Pan troglodytes*; CSAC 2.1.4/panTro4), Gorilla (*Gorilla gorilla gorilla*; gorGor3.1/gorGor3), Orangutan (*Pongo pygmaeus abelii*; WUGSC 2.0.2/ponAbe2), Gibbon (*Nomascus leucogenys*; GGSC Nleu3.0/nomLeu3), Rhesus (*Macaca mulatta*; BGI CR_1.0/rheMac3), Baboon (*Papio hamadryas*; Baylor Pham_1.0/papHam1), Marmoset (*Callithrix jacchus*; WUGSC 3.2/calJac3), Squirrel monkey (*Saimiri boliviensis*; Broad/saiBol1), Tarsier (*Tarsius syrichta*; Tarsius_syrichta2.0.1/tarSyr2), Bushbaby (*Otolemur garnettii*; Broad/otoGar3), Mouse lemur (*Microcebus murinus*; Broad/micMur1), Chinese tree shrew (*Tupaia chinensis*; TupChi_1.0/tupChi1), Squirrel (*Spermophilus tridecemlineatus*; Broad/speTri2), Mouse (*Mus musculus*; GRCm38/mm10), Rat (*Rattus norvegicus*; RGSC 5.0/rn5), Naked mole-rat (*Heterocephalus glaber*; Broad HetGla_female_1.0/hetGla2), Guinea pig (*Cavia porcellus*; Broad/cavPor3), Rabbit (*Oryctolagus cuniculus*; Broad/oryCun2), Pika (*Ochotona princeps*; OchPri3.0/ochPri3), Kangaroo rat (*Dipodomys ordii*; Broad/dipOrd1), Chinese hamster (*Cricetulus griseus*; C_griseus_v1.0/criGri1), Pig (*Sus scrofa*; SGSC Sscrofa10.2/susScr3), Alpaca (*Vicugna pacos*; Vicugna_pacos-2.0.1/vicPac2), Dolphin (*Tursiops truncatus*; Baylor Ttru_1.4/turTru2), Cow (*Bos taurus*; Baylor Btau_4.6.1/bosTau7), Sheep (*Ovis aries*; ISGC Oar_v3.1/oviAri3), Horse (*Equus caballus*; Broad/equCab2), White rhinoceros (*Ceratotherium simum*; CerSimSim1.0/cerSim1), Cat (*Felis catus*; ICGSC Felis_catus 6.2/felCat5), Dog (*Canis lupus familiaris*; Broad CanFam3.1/canFam3), Ferret (*Mustela putorius furo*; MusPutFur1.0/musFur1), Panda (*Ailuropoda melanoleuca*; BGI-Shenzhen 1.0/ailMel1), Megabat (*Pteropus vampyrus*; Broad/pteVam1), Microbat (*Myotis lucifugus*; Broad Institute Myoluc2.0/myoLuc2), Hedgehog (*Erinaceus europaeus*; EriEur2.0/eriEur2), Shrew (*Sorex araneus*; Broad/sorAra2), Minke whale (*Balaenoptera acutorostrata scammoni*; balAcu1), Bowhead Whale (*Balaena mysticetus*; v1.0), Rock hyrax (*Procavia capensis*; Broad/proCap1), Sloth (*Choloepus hoffmanni*; Broad/choHof1), Elephant (*Loxodonta africana*; Broad/loxAfr3), Cape elephant shrew (*Elephantulus edwardii*; EleEdw1.0/eleEdw1), Manatee (*Trichechus manatus latirostris*; Broad v1.0/triMan1), Tenrec (*Echinops telfairi*; Broad/echTel2), Aardvark (*Orycteropus afer afer*; OryAfe1.0/oryAfe1), Armadillo (*Dasypus novemcinctus*; Baylor/dasNov3), Opossum (*Monodelphis domestica*; Broad/monDom5), Tasmanian devil (*Sarcophilus harrisii*; WTSI Devil_ref v7.0/sarHar1), Wallaby (*Macropus eugenii*; TWGS Meug_1.1/macEug2), Platypus (*Ornithorhynchus anatinus*; WUGSC 5.0.1/ornAna1), Medium ground finch (*Geospiza fortis*; GeoFor_1.0/geoFor1), Zebra finch (*Taeniopygia guttata*; WashU taeGut324/taeGut2), Budgerigar (*Melopsittacus undulatus*; WUSTL v6.3/melUnd1), Chicken (*Gallus gallus*; ICGSC Gallus_gallus-4.0/galGal4), Turkey (*Meleagris gallopavo*; TGC Turkey_2.01/melGal1), American alligator (*Alligator mississippiensis*; allMis0.2/allMis1), Painted turtle (*Chrysemys picta bellii*; v3.0.1/chrPic1), Lizard (*Anolis carolinensis*; Broad AnoCar2.0/anoCar2), X. tropicalis (*Xenopus tropicalis*; JGI 7.0/xenTro7), Coelacanth (*Latimeria chalumnae*; Broad/latCha1).

*TP53/TP53RTG* copy number estimation in proboscidean genomes {#s4-2}
-------------------------------------------------------------

### Identification of TP53/TP53RTG genes in the Asian elephant genome {#s4-2-1}

We used previously published whole genome shotgun sequencing data from an Asian elephant (Elephas maximus) generated on an Illumina HiSeq 2000{\'Hou\'} to estimate the *TP53/TP53RTG* copy number in the genome. For these analyses, we combined data from two individual elephants (ERX334765 and ERX334764) into a single dataset of 151,482,390 76-nt paired end reads. We then mapped Asian elephant reads onto the African elephant *TP53/TP53RTG* genes using Bowtie2 in paired-end mode, with the local alignment and 'very sensitive' options and Cufflinks (version 0.0.7) to assemble mapped reads into genes which we treated as putative Asian elephant orthologs. We identified 14 putative 1:1 orthologous TP53RTG genes in the Asian elephant genome, including *TP53RTG1, TP53RTG2, TP53RTG3, TP53RTG4, TP53RTG5, TP53RTG6, TP53RTG9, TP53RTG10, TP53RTG11, TP53RTG13, TP53RTG14, TP53RTG17, TP53RTG18, and TP53RTG19*.

### Identification of TP53/TP53RTG genes in the Columbian and woolly mammoth genomes {#s4-2-2}

We used previously published whole genome shotgun sequencing data from an \~11,000 year old Columbian mammoth (*Mammuthus columbi*) generated on an Illumina HiSeq 1000{\'Sparks\'} to estimate the *TP53/TP53RTG* copy number in the genome. For these analyses, we combined data from three individual mammoths (SRX329134, SRX329135, SRX327587, SRX327586, SRX327583, SRX327582) into a single dataset of 158,704,819 102-nt paired end reads. We then mapped Asian elephant reads onto the African elephant *TP53/TP53RTG* genes using Bowtie2 in paired-end mode, with the local alignment and 'very sensitive' options, and Cufflinks (version 0.0.7) to assemble mapped reads into genes which we treated as putative Asian elephant orthologs. We identified 14 putative 1:1 orthologous *TP53RTG* genes in the Columbian mammoth genome, including *TP53RTG10, TP53RTG11, TP53RTG13, TP53RTG14, TP53RTG16, TP53RTG17, TP53RTG19, TP53RTG2, TP53RTG3, TP53RTG4, TP53RTG5, TP53RTG6, TP53RTG8, TP53RTG9*.

### Identification of TP53/TP53RTG genes in the American mastodon genome {#s4-2-3}

We used previously published whole genome shotgun sequencing data generated on a Roche 454 Genome Sequencer (GS FLX) to estimate the TP53 copy number in a 50,000--130,000 year old American mastodon (Mammut americanum){\'Langmead\'}. To estimate TP53 copy number we combined 454 sequencing data from 'Library A' (SRX015822) and 'Library B' (SRX015823) into a single dataset of 518,925 reads. Reads were converted from FASTQ to FASTA and aligned to African elephant *TP53* gene and retrogene sequences using Lastz. We used the 'Roche-454 90% identity' mapping mode, not reporting matches lower than 90% identity. Three American mastodon reads were identified that mapped to at least one TP53 gene/retrogene. The likely identities of these reads were determined by using BLAT to map their location in the African elephant (Broad/loxAfr3) genome; mastodon reads mapping to a single elephant gene with \>98% identity were considered likely mastodon orthologs. This strategy mapped one read to the *TP53TRG8* retrogene, one read to the either the *TP53TRG3* or *TP53RTG10* retrogenes, and one read to the *TP53TRG6* retrogene.

### Gene tree reconciliation {#s4-2-4}

For gene tree reconciliation putative Asian elephant, Columbian mammoth, and woolly mammoth *TP53/TP53RTG* orthologs were manually placed into the African elephant *TP53/TP53RTG* gene tree. We then used Notung v2.6 ([@bib12]) to reconcile the gene and species trees, and interpreted Asian elephant-, Columbian mammoth-, and wooly mammoth-specific gene losses as unsampled *TP53RTG* genes if the putative divergence date of the ortholog predated the African-(Asian elephant/Mammoth) divergence. We thus inferred two unsampled genes (*TP53RTG7* and *TP53RTG8*) in the Asian elephant genome, and three unsampled genes (*TP53RTG18*, *TP53RTG7* and *TP53RTG1*) in the Columbian mammoth genome. Note that this method will estimate the minimum number of *TP53/TP53RTG* genes in the genome because our mapping strategy cannot identify lineage specific duplications after each species diverged from the African elephant lineage. Finally, we used Notung v2.6 ([@bib12]) to reconcile the gene and species trees, and interpreted lineage-specific gene losses as unsampled *TP53RTG* genes (i.e., genes present in the genome but missing from the aDNA sequencing data). This process was modified slightly for American mastodon, such that 'lost' *TP53RTG* genes younger than the mastodon-elephant split were considered elephant-specific paralogs rather than unsampled genes present in the mastodon genome.

### Normalized read depth {#s4-2-5}

We also used normalized mapped read depth to estimate *TP53/TP53RTG* copy number. Unlike gene tree reconciliation, copy number estimates based on read depth cannot resolve the orthology of specific *TP53/TP53RTG* copies but can estimate the total number of *TP53/TP53RTG* copies in the genome and thus provide evidence of lineage specific copy number changes. For this analyses, we mapped Asian elephant-, Columbian mammoth-, and woolly mammoth-specific reads onto the African elephant *TP53/TP53RTG* genes using Bowtie 2 ([@bib45]) with the local alignment and 'very sensitive' options and Cufflinks (version 0.0.7) ([@bib81]) to assemble mapped reads into genes. We then summed the read depth ('coverage') of *TP53RTG* genes and normalized this summed *TP53RTG* read depth to the read depth of five single copy genomic regions equal in length to average *TP53RTG* gene length. This ratio represents an estimate of the *TP53/TP53RTG* copy number in the genome.

Correlation between *TP53/TP53RTG* copy number and body size evolution {#s4-3}
----------------------------------------------------------------------

Relative divergence (duplication) times of the TP53 retrogenes were estimated using the TP53 alignment described above and BEAST (v1.7.4) ([@bib71]). We used the general time reversible model (GTR), empirical nucleotide frequencies (+F), a proportion of invariable sites estimated from the data (+I), four gamma distributed rate categories (+G), an uncorrelated lognormal relaxed molecular clock to model substitution rate variation across lineages, a Yule speciation tree prior, uniform priors for the GTR substitution parameters, gamma shape parameter, proportion of invariant sites parameter, and nucleotide frequency parameter. We used an Unweighted Pair Group Arithmetic Mean (UPGMA) starting tree.

To obtain posterior distributions of estimated divergence times, we use five node calibrations modeled as normal priors (standard deviation = 1) to constrain the age of the root nodes for the Eutheria (104.7 MYA), Laurasiatheria (87.2 MYA), Boreoeutherian (92.4 MYA), Atlantogenatan (103 MYA), and Paenungulata (64.2 MYA); divergence dates were obtained from [www.timetree.org](http://www.timetree.org) using the 'Expert Result' divergence dates. The analysis was run for 5 million generations and sampled every 1000 generations with a burn-in of 1 million generations; convergence was assessed using Tracer, which indicated convergence was reached rapidly (within 100,000 generations). Proboscidean body size data were obtained from previously published studies on mammalian body size evolution ([@bib25]).

Inference of *TP53/TP53RTG* copy number expansion through segmental duplications {#s4-4}
--------------------------------------------------------------------------------

We also observed that the genomic region surrounding each *TP53RTG* gene contained blocks of homolgous transposable element insertions, suggesting that these regions are segmental duplications. To confirm this observation, we used MUSCLE ([@bib22]) to align an approximately 20 kb region surrounding each *TP53RTG* gene and found that conservation within this region was very high, again suggesting these regions are relatively recent segmental duplications. To identify if the contigs on which *TP53RTG* genes are located contained locally collinear blocks (LCBs), as expected for segmental duplications, we aligned contigs using progressiveMAUVE ([@bib18]) as implemented in Genious (v6.1.2).

Phylogenetic analyses of *TP53/TP53RTG* genes {#s4-5}
---------------------------------------------

We generated a dataset of *TP53* orthologs from 65 diverse mammals identified from GenBank, and included the *TP53* genes and retrogenes we identified from the African elephant, hyrax, manatee, tenrec, cape elephant shrew, and armadillo genomes. Nucleotide sequences were aligned using the MAFFT algorithm ([@bib38]) and the FFT refinement strategy implemented in the GUIDANCE webserver ([@bib62]). Alignment confidence was assessed with 100 bootstrap replicates and ambiguously aligned sites (under the default GUIDANCE exclusion rule) removed prior to phylogenetic analyses; lineage specific insertions and deletions were also removed prior to phylogenetic analyses.

TP53 phylogenies were inferred using maximum likelihood implemented in PhyML (v3.1) ([@bib33]) using a general time reversible model (GTR), empirical nucleotide frequencies (+F), a proportion of invariable sites estimated from the data (+I), four gamma distributed rate categories (+G), and using the best of NNI and SPR branch moves during the topology search. Branch supports were assessed using the aBayes, aLRT, SH-like, and Chi2-based 'fast' methods as well as 1000 bootstrap replicates ([@bib33]). We also used MrBayes (v3.2.2 x64) ([@bib37]) for Bayesian tree inference using the GTR+I+G model; the analysis was run with two simultaneous runs of four chains for 4 million generations with the chains sampled every 1000 generations. We used Tracer (v1.5) to assess when the chains reached stationarity, which occurred around generation 100,000. At completion of the run the PRSF value was 1.00 indicating the analyses had reached convergence.

Gene expression data (RNA-Seq) {#s4-6}
------------------------------

To determine if *TP53RTG* genes were expressed, we generated RNA-Seq data from term placental villus and adipose tissue from African elephants (*Loxodonta africana*) and primary dermal fibroblasts from Asian elephants (*Elepas maximus*). Briefly, sequencing libraries were prepared using standard Illumina protocols with poly(A) selection, and sequenced as 100 bp single-end reads on a HiSeq2000. We also used previously published RNA-Seq data generated from primary fibroblasts (isolated from ear clips) from a male (GSM1227965) and female (GSM1227964) African elephant generated on an Illumina Genome Analyzer IIx (101 cycles, single end) and a male (GSM1278046) African elephant generated on an Illumina HiSeq 2000 (101 cycles, single end) ([@bib16]) and combined these reads into a single dataset of 138,954,285 reads. Finally, we used previously published 100 bp single-end reads generated on a HiSeq2000 to identify *TP53RTG* transcripts from Asian elephant PBMCs (SRX1423033) ([@bib68]).

Reads were aligned to a custom built elephant reference gene set generated by combining the sequences of the canonical *TP53* gene and *TP53RTG* genes with the ENSEMBL African elephant (*Loxodonta africana*) CDS gene build (Loxodonta_africana.loxAfr3.75.cds.all.fa) with Bowtie2 ([@bib45]). Bowtie two settings were: (1) both local alignment and end-to-end mapping; (2) preset option: sensitive; (3) Trim n-bases from 5\' of each read: 0; and (4) Trim n-bases from 3\' of each read: 0. Transcript assembly and FPKM estimates were generated with Cufflinks (version 0.0.7) ([@bib81]) using aligned reads from Bowtie2, non-default parameters included quartile normalization and multi-read correction. Finally, we transformed FPKM estimates into transcripts per million (TPM), TPM=(FPKM per gene/sum FPKM all genes)x10^6^, and defined genes with TPM ≥ 2 as expressed ([@bib47]; [@bib83], [@bib84]).

The TP53RTG genes are 80.0--82.7% identical to TP53 at the nucleotide level, with 204--231 total nucleotide differences compared to TP53. This level of divergence allows for many reads to be uniquely mapped to each gene, there will also be significant read mapping uncertainty in regions of these genes with few nucleotide differences. However, if read mapping uncertainty was leading to false positive mappings of *TP53* derived reads to *TP53RTG* genes we would expect to observe the expression of many *TP53RTG* genes, rather the robust expression of a single (*TP53RTG12*) gene. We also counted the number of uniquely mapped reads to each *TP53RTG* gene and *TP53*. We found that 0--8 reads were uniquely mapped to most TP53RTG genes, except *TP53RTG12* which had \~115 uniquely mapped reads across samples and TP53 which had \~3000 uniquely mapped reads across tissue samples. Thus we conclude that read mapping uncertainty has not adversely affected our RNA-Seq analyses.

Gene expression data (PCR and Sanger sequencing) {#s4-7}
------------------------------------------------

We further confirmed expression of *TP53RTG12* transcripts in elephant cells through RT-PCR, taking advantage of differences between *TP53RTG12* and *TP53* sequences to design two aligned primer sets, one TP53-specific, the other *TP53RTG12* specific. *TP53RTG12* primers were: 5´ *ggg gaa act cct tcc tga ga* 3´ (forward) and 5´ *cca gac aga aac gat agg tg* 3´ (reverse). TP53 primers were: 5´ *atg gga act cct tcc tga ga* 3´ (forward) and 5´ *cca gac gga aac cat agg tg* 3´ (reverse). The *TP53* amplicon is expected to be 251 bps in length, while deletions present in the *TP53RTG12* sequence lead to a smaller projected amplicon size of 220 bps.

Total RNA was extracted from cultured *Loxodonta* and *Elephas* fibroblasts (RNAeasy Plus Mini kit, Qiagen), then DNase treated (Turbo DNA-free kit, Ambion) and reverse-transcribed using an olgio-dT primer for cDNA synthesis (Maxima H Minus First Strand cDNA Synthesis kit, Thermo Scientific). Control RT reactions were otherwise processed identically, except for the omission of reverse transcriptase from the reaction mixture. RT products were PCR-amplified for 45 cycles of 94°/20 s, 56°/30 s, 72°/30 s using a BioRad CFX96 Real Time qPCR detection system and SYBR Green master mix (QuantiTect, Qiagen). PCR products were electrophoresed on 3% agarose gels for 1 hr at 100 volts, stained with SYBR safe, and imaged in a digital gel box (ChemiDoc MP, BioRad) to visualize relative amplicon sizes. PCR products were also directly sequenced at the University of Chicago Genomics core facility, confirming projected product sizes and sequence identities.

Gene prediction, promoter annotation, and TP53RTG transcript identification {#s4-8}
---------------------------------------------------------------------------

We used geneid v1.2 (<http://genome.crg.es/software/geneid/geneid.html>) to infer if the *TP53RTG12* gene contained a non-coding exon 5' to the predicted ATG start codon. For gene structure prediction we used the full-length scaffold_825 from African elephant (Broad/loxAfr3) sequence and forced an internal exon where the *TP53RTG12* gene is encoded in scaffold_825. Geneid identified a putative exon 5' to the *TP53RTG12* gene from nucleotides 1761--1935 and an exon 3' from nucleotides 6401--6776. We also used GENESCAN (<http://genes.mit.edu/cgi-bin/genscanw_py.cgi>) to predict the location of exons in the full-length scaffold_825 sequence and identified a putative exon from nucleotides 1750--1986. We next used Bowtie2 ([@bib45]) to map African and Asian elephant fibroblast RNA-Seq data onto African elephant scaffold_825 with the default settings.

Taxonomic distribution of the RTE1_LA retrotransposon {#s4-9}
-----------------------------------------------------

The RTE1_LA non-LTR retrotransposon has previously been described from the African elephant genome, these elements are generally more than 90% identical to the consensus RTE1_LA sequence but less than 70% identical to other mammalian RTEs (<http://www.girinst.org/2006/vol6/issue3/RTE1_LA.html>). These data suggest that the RTE_LA element has relatively recently expanded in the elephant genome. To determine the taxonomic distribution of the RTE1_LA element we used BLAT to search the lesser hedgehog tenrec (*Echinops telfairi*), rock hyrax (*Procavia capensis*), West Indian manatee (*Trichechus manatus*), armadillo (*Dasypus novemcinctus*), and sloth (*Choloepus hoffmanni*) genomes. We identified numerous copies of the RTE_LA element in the genome of the Afrotherians, but not the Xenarthran genomes. These data indicate that the RTE_LA element is Afrotherian-specific, rather than Elephant-specific.

TP53/TP53RTG western blotting {#s4-10}
-----------------------------

Elephant and Hyrax primary fibroblasts (San Diego Zoo, \'Frozen Zoo\') were grown to confluency in 10 cm dishes at 37°C/5% CO~2~ in a culture medium consisting of FGM/EMEM (1:1) supplemented with insulin, FGF, 6% FBS and Gentamicin/Amphotericin B (FGM-2, singlequots, Clonetics/Lonza). Culture medium was removed from dishes just prior to UV treatment and returned to cells shortly afterwards. Experimental cells were exposed to 50 J/m^2^UV-C radiation in a crosslinker (Stratalinker 2400, Stratagene), while control cells passed through media changes but were not exposed to UV. A small volume (\~3 mL) of PBS covered fibroblasts at the time of UV exposure. To inhibit TP53 proteolysis, MG-132 (10 µM) was added to experimental cell medium 1 hr prior to UV exposure, and maintained until the time of cell lysis. 5 hr post-UV treatment, cells were briefly rinsed in PBS, then lysed and boiled in 2x SDS-PAGE sample buffer. Lysates were separated via SDS-PAGE on 10% gels for 1 hr at 140 volts, then electrophoretically transferred to PVDF membranes (1 hr at 85 volts). Membranes were blocked for 1 hr in 5% milk in TBST and incubated overnight at 4°C with rabbit polyclonal TP53 antibodies (FL-393, Santa Cruz Biotechnology, and ab131442, Abcam). Blots were washed 3x in TBST, incubated with HRP-conjugated, anti-rabbit IgG 2° antibodies for 1 hr at RT, and washed four more times in TBST. Protein bands were visualized via enhanced chemiluminescence (BioRad Clarity), and imaged in a digital gel box (Chemidoc MP, BioRad). Western blots were replicated three independent times.

Co-immunoprecipitation {#s4-11}
----------------------

Human HEK-293 cells were grown to 80% confluency in 20 cm dishes at 37°C/5% CO~2~ in a culture medium consisting of DMEM supplemented with 10% FBS. At 80% confluency, cells were transiently transfected with the TP53RTG12 pcDNA3.1(+)/myc-His expression vector. After 16 hr the transfection media was removed and replaced with fresh DMEM, and the cells were incubated an additional 24 hr before harvesting. After removing DMEM and washing cells twice with PBS, 1 mL ice-cold lysis buffer (20 mM Tris, pH 8.0, 40 mM KCl, 10 mM MgCl2, 10% glycerol, 1% Triton X-100, 1x Complete EDTA-free protease inhibitor cocktail (Roche), 1x PhosSTOP (Roche)) was added to each plate and cells were harvested by scraping with a rubber spatula. Cells were then incubated on ice for 30 min in 420 mM NaCl. The whole cell lysate was cleared by centrifugation at 10,000 rpm for 30 min at 4°C, and the supernatant was transferred to a clean microfuge tube. After equilibrating protein concentrations, 1 mL of sample was mixed with 40 mL of α-MDM2 or α-Myc antibody conjugated agarose beads (Sigma) pre-washed with TNT buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.05% Triton X-100), and rotated overnight at 4°C. The following day, samples were treated with 50 U DNase (Roche) and 2.5 μg RNase (Roche) for 60 min at room temperature, as indicated. Samples were washed 3x with 1 mL wash buffer (150 mM NaCl, 0.5% Triton X-100). After the final wash, agarose beads were resuspended in elution buffer (500 mM Tris pH 7.5, 1 M NaCl), and boiled to elute immunoprecipitated complexes. Eluted protein was run on Bis-tris gels, probed with antibodies and visualized by Chemi-luminescence. Serial Westerns were performed for each antibody following chemical stripping and re-blocking. Antibodies were from Santa Cruz: MDM2 (SMP14) sc-965, lot \#J2314; p53 (Fl-393) sc-6243, lot \# D0215; c-Myc (9E10) sc-40, lot \# G2413.

ApoTox-Glo viability/cytotoxicity/apoptosis analyses {#s4-12}
----------------------------------------------------

Primary fibroblasts were grown to 80% confluency in T-75 culture flasks at 37°C/5% CO~2~ in a culture medium consisting of FGM/EMEM (1:1) supplemented with insulin, FGF, 6% FBS and Gentamicin/Amphotericin B (FGM-2, singlequots, Clonetics/Lonza). 10^4^ cells were seeded into each well of an opaque bottomed 96-well plate, leaving a column with no cells (background control); each 96-well plate contained paired elephant and hyrax samples. Serial dilutions of Doxorubicin (0 uM, 0.5 uM, 1.0 uM, 5 uM, 10 uM and 50 uM), Mitomycin c (0 uM, 0.5 uM, 1.0 uM, 5 uM, 10 uM and 50 uM), and Nutlin-3a (0 uM, 0.5 uM, 1.0 uM, 5 uM, 10 uM and 50 uM) and 90% culture media were added to each well such that there were four biological replicates for each condition. After 18 hr of incubation with each drug, cell viability, cytotoxicity, and caspase-3/7 activity were measured using the ApoTox-Glo Triplex Assay (Promega) in a GloMax-Multi+ Reader (Promega). Data were standardized to no-drug control cells. For UV-C treatment, culture medium was removed from wells prior to UV treatment and returned to cells shortly afterwards. Experimental cells were exposed to 50 J/m^2^UV-C radiation in a crosslinker (Stratalinker 2400, Stratagene), while control cells passed through media changes but were not exposed to UV. A small volume (\~30 uL) of PBS covered fibroblasts at the time of UV exposure. Cell viability, cytotoxicity, and caspase-3/7 activity were measured using the ApoTox-Glo Triplex Assay (Promega) in a GloMax-Multi+ Reader (Promega) 6, 12, 28.5 and 54.5 hr after UV-C treatment. Data were standardized to no UV-C exposure control cells. ApoTox-Glo Triplex Assays were replicated three independent times.

Luciferase assays {#s4-13}
-----------------

Primary fibroblasts were grown to 80% confluency in T-75 culture flasks at 37°C/5% CO~2~ in a culture medium consisting of FGM/EMEM (1:1) supplemented with insulin, FGF, 6% FBS and Gentamicin/Amphotericin B (FGM-2, singlequots, Clonetics/Lonza). At confluency, cells were trypsinized, centrifuged at 90 g for 10 min and resuspended in nucleofection/supplement solution and incubated for 15 min. After incubation 1ug of the pGL4.38\[*luc2p*/p53 RE/Hygro\] luciferase reporter vector and 100 ng of the pGL4.74\[*hRluc*/TK\] Renilla reporter vector were transiently transfected into an elephant and hyrax cells using the Amaxa Basic Nucleofector Kit (Lonza) using protocol T-016. Immediately following nuleofection, 10^4^ cells were seeded into each well of an opaque bottomed 96-well plate, leaving a column with no cells (background control); each 96-well plate contained paired elephant and hyrax samples. 24 hr after nucleofection cells were treated with either vehicle control, Doxorubicin, Mitomycin c, Nutlin-3a, or 50 J/m^2^UV-C. Luciferase expression was assayed 18 hr after drug/UV-C treatment cells, using the Dual-Luciferase Reporter Assay System (Promega) in a GloMax-Multi+ Reader (Promega). For all experiments luciferase expression was standardized to Renilla expression to control for differences nucleofection efficiency across samples; Luc./Renilla data is standardized to (Luc./Renilla) expression in untreated control cells. Each luciferase experiment was replicated three independent times.

siRNA experiments {#s4-14}
-----------------

siRNAs designed to specifically-target TP53RTG were validated via qRT-PCR using the two primer sets described earlier, which amplify either TP53RTG or canonical TP53 cDNAs, to confirm specificity and efficacy of knockdown. Sequences of the three TP53RTG-specific siRNAs used are as follows: (1) 5'-CAGCGGAGGCAGUAGAUGAUU-3', (2) 5'-GGCUCAAGGAAUAUCAGAAUU-3', (3) 5'-CAGCAGCGGAGGCAGUAGAUU-3' (Dharmacon). Loxodonta fibroblasts were transfected with siRNAs using Lipofectamine LTX, and tested 48--72 hr later for either TP53 response via luciferase assay or for cell viability/toxicity/apoptosis via ApoTox-Glo assay.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your work entitled \"TP53 duplication correlates with the evolution of increased body size and an enhanced DNA damage response in elephants\" for consideration by *eLife*. Your article has been favorably evaluated by Diethard Tautz as the Senior Editor and three reviewers, one of whom is a member of our Board of Reviewing Editors.

The reviewers have discussed the reviews with one another and the Reviewing editor has drafted this decision to help you prepare a revised submission.

The reviewers discussed the manuscript at length, and found it to be very interesting and likely to become a major contribution to the field of evolutionary medicine. One of the reviewers pointed out that some of the findings in the manuscript were likely to become material for biology textbooks. Another Reviewer described the findings as \'fascinating\' and \'inspiring\'.

The manuscript describes the interesting fact that the tumor suppressor gene TP53 has undergone significant copy number gain in the elephant (Proboscidean) lineage, which may solve the so-called Peto\'s paradox, i.e. the lack of correlation between body size/lifespan and tumor incidence in the animal kingdom. The manuscript documents several interesting findings, including:

a\) Expansion of the p53 gene via segmental duplication of \'retrogenes\'.

b\) Existence of a promoter sequence enabling transcription of these additional copies.c) Expression analysis of the retrogenes via RNAseq and PCR.

d\) Increased protein expression of \'retroproteins\' after DNA damage by UVC.

e\) Increased p53 reporter activity and apoptosis in response to diverse p53 activating agents.

f\) Evidence of a \'transdominant\' effect, whereas the truncated protein \'retroproteins\' may enhance p53 activity by protecting it from MDM2-mediated repression.

The reviewers discussed the fact that during the review process a similar paper was published by the Schiffman group. However, the reviewers concluded that the current manuscript by Sulak et al. contains significantly more information, and that it also reaches somewhat different conclusions about the expression and mechanism of action of the p53 retrogenes. Accordingly, the reviewers agreed to recommend submission of a revised manuscript that would not only address several concerns about experimental design and data analysis, but that would also contain an exhaustive comparison and discussion of the findings in the two papers.

The key concerns raised by reviewers are:

A\) Comparison and discussion of the findings in the current manuscript versus those in the paper by the Schiffman team. Reviewers concluded that it would be critical for readers to clearly understand the additional information in this paper, as well as the areas of conflicting observations that may require future investigation. The paper from Schiffman et al. needs to be cited and acknowledged in the current manuscript. Reviewers observed that since this paper complements and extends the published work in significant ways, it may well end up being more highly cited, and that proper citation practice would be to cite both of these together. Some examples of the aspects that should be compared between the two papers are:

A1) The current manuscript contains an elegant demonstration of the mechanism of copy number gain via segmental duplication, which should be highlighted. The results described in the first three subsections of the Results section, on the phylogenetic origin and the association of increased copy number with increased body size provide independent added value that goes beyond the Schiffman.

A2) Some of these results on RTG expression are more precise than those reported in the Schiffman et al. paper. The authors need to go over the supplementary material as well as the results in the published paper and point out where they agree, where they do not, and where these results extend the results from Schiffman et al. For example, using RNA-seq, the authors show that the retrogene RTG12 is the variant most predominantly transcribed in elephant cells. In contrast, Schiffman et al. employed RT-PCR to document expression of \'retrogenes\'. How many of the retrogenes are actually expressed? Is it possible that retrogenes are expressed in a cell type-specific manner (e.g. fibroblasts in this paper versus lymphoblastoids in Schiffman\'s paper?).

B\) Unclear mechanism of action of the retrogene-encoded p53 variants. The two papers disagree on the mechanism of action of the retrogene-encoded proteins. Here, the authors describe a \'transdominant\' effect that does not involve MDM2 binding. In contrast, the work by Schiffman et al. concludes that the retroproteins do bind to MDM2. The data from both papers is weak in this regard. If RTG12 does not bind to MDM2 as indicated in this paper, how is then its expression controlled upon DNA damage? What is the mechanism by which UVC leads to significantly more expression of RTG12? To address this issue, the authors should test whether RTG12 induction is at the level of RNA or protein stability, and to define whether Nutlin (an inhibitor of the MDM2-p53 interaction) also induces protein accumulation in this setting. Furthermore, their current model does not include stabilization of RTG12 protein upon DNA damage. How does RTG12 in this manuscript compare to RTG9 in the paper by Schiffman et al? Could it be that differences in putative binding to MDM2 among the two papers are due to sequence variations in the N-terminus domain of the various retroproteins? To address this, the reviewers request a figure showing aminoacid and nucleotide alignments of the N-terminus transactivation domain regions for all RTGs, highlighting the residues known to be important for transactivation and binding to MDM2, and including all proper Genbank identifiers for each sequence. One of the reviewers pointed out that the MDM2 binding site is mutated in all the TP53RTG proteins (for those that initiate at the first ATG). Furthermore, the same Reviewer observed that, from analysis of the sequences available in Genbank, all the TP53RTGs except one can produce a protein of at least 79 amino-acids, as some TP53RTG can be translated from codon 728 or 940. This should be discussed in the revised manuscript. To further support their \'transdominant\' mechanism, the authors should simply perform co-immunoprecipitation of full-length p53 protein using the C-terminal p53-specific 421 monoclonal antibody (the epitope is conserved in the elephant p53 protein). The 421 antibody will not bind to TP53RTG proteins, which lack the 421 epitope. Thus, the co-immunoprecipitation of TP53RTG proteins with full-length elephant p53 protein will unequivocally prove the formation of a protein complex with full-length p53. Finally, the authors propose that the TP53RTG proteins inhibit tetramerization of p53. However, tetramerization of p53 is absolutely required for p53 transcriptional activity. In addition, MG132 seems to induce ubiquitination of p53 in elephant cells treated with DNA-damaging agents despite expression of TP53RTG12. Therefore, the model involving inhibition of tetramerization and ubiquitination is not possible. Altogether, the experiments proposed here will enable the authors to produce a more accurate model of p53 regulation by the p53 retroproteins in elephant cells.

C\) Concern about the use overexpression experiments and HEK293 cells. Reviewers were concerned about the use of ectopic overexpression of TP53RTG12 in mouse cells and human HEK293 cells. The observed phenotypes (e.g. hypersensitivity to DNA damage) could be due to artifact-prone overexpression analysis. In addition, it is well established that p53 is inactivated and stabilized by a viral transforming protein in HEK293 cells. Therefore, the value of the MDM2 experiments conducted in HEK293 cells is unclear. In order to unequivocally demonstrate that TP53RTGs regulate the p53-dependent cellular response to DNA damage, the authors must knockdown endogenous TP53RTG expression using TP53RTG-specific siRNAs in elephant cells. Since the authors have identified long nucleotide sequences unique to TP53RTG mRNAs, it is then possible to design siRNAs that will reduce TP53RTG expression without affecting TP53 expression in elephant cells. It will be possible then for the authors to test their hypothesis in elephant cells. Furthermore, transfection of TP53RTG siRNA would enable the authors to unequivocally identify the protein bands corresponding to TP53RTG proteins via Western blot.

D\) Interpretation of the various \'protein bands\' observed in elephant cells. In addition to the siRNA experiments mentioned above, reviewers pointed out that the authors cannot accurately identify and name the p53 isoforms observed in their electrophoresis experiments. The elephant p53 protein has no methionine at codon133 and p53psy has not been demonstrated in elephant cells. Furthermore, the bands above 50kD may be polymers or ubiquitinated p53 proteins or cross-reacting bands. Thus, it is essential to define the identity of these bands with TP53 siRNAs (the C-terminal region would provide ample sequence space to design these siRNAs). Also, the protein molecular weight marker is not displayed in any of the immunoblots, which prevents proper interpretation of these results.

E\) Incomplete discussion of the impact of p53 copy number gain in organismal biology, tumor suppression and ageing/senescence. The p53 literature abounds with studies exploring the impact of additional copies of the p53 gene, including \'retrogenes\'. The reviewers concluded that this manuscript would be much improved by a thorough discussion of these studies. For example, the authors should discuss the p53 pseudogenes in mouse and rat, which are expressed and seem to compromise the activity of functional p53. Importantly, it is well established that an extra copy of full-length p53 in mice leads to hyperactive apoptotic activity, shortening the lifespan of the organism and also inducing neurodegenerative diseases. Thus, the authors should discuss the \'super p53\' mouse models (García-Cao et al., EMBO J 2002; Tyner et al., Nature 2002; Maier et al. Genes and Dev 2004).

Another important point in this area is that the authors have not discussed the fact that TP53RTG12 seems to be the only highly expressed p53 pseudogene in elephant cells. How could the authors conclude that the low cancer incidence in elephants is due to the \'multiple copies\' of p53 pseudogenes, while the effects of all TP53RTGs seem to be driven by a single retrogene, TP53RTG12? In fact, the authors show that all the TP53RTGs are expressed in the RNA seq data -although at very variable levels-, and they should emphasize this observation; otherwise the story does not reconcile with the existence of two expressed p53 pseudogenes in rat and the two or single expressed p53 pseudogenes in mouse (Tanooka et al., Cancer Res. 1998 and Gene 2001). The authors made a very important discovery, as elephant species may have evolved a molecular mechanism to uncouple the tumor suppressive activity of p53 from its pro-ageing activity. Therefore, the authors should elaborate on whether it is the number of RTGs and/or the tissue specific expression of RTGs and/or the type of RTG (i.e. as defined by the amino-acid sequence of the RTG) that fine tunes p53 activities toward enhanced tumor suppression without hyper-reactivity to cellular stress.
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Author response

*The reviewers discussed the fact that during the review process a similar paper was published by the Schiffman group. However, the reviewers concluded that the current manuscript by Sulak et al. contains significantly more information, and that it also reaches somewhat different conclusions about the expression and mechanism of action of the p53 retrogenes. Accordingly, the reviewers agreed to recommend submission of a revised manuscript that would not only address several concerns about experimental design and data analysis, but that would also contain an exhaustive comparison and discussion of the findings in the two papers.*

We thank the editors for the opportunity to revise and resubmit our manuscript.

We have modified the main text, specifically the Results and Discussion sections, to address reviewer comments including the addition of several new experiments, and expanded details of results to clarify reviewer concerns and misunderstandings. Among the new experiments are a demonstration that TP53RTG genes are necessary for the augmented TP53 signaling response in elephants via siRNA-mediated knock-down of TP53RTG transcripts and a detailed structural and functional comparison of our model of TP53RTG mechanism of action vs the model proposed by the Abegglen et al. (2015). We elaborate on these additional experiments as well as other changes below.

*The key concerns raised by reviewers are:*

*A) Comparison and discussion of the findings in the current manuscript versus those in the paper by the Schiffman team. Reviewers concluded that it would be critical for readers to clearly understand the additional information in this paper, as well as the areas of conflicting observations that may require future investigation. The paper from Schiffman et al. needs to be cited and acknowledged in the current manuscript. Reviewers observed that since this paper complements and extends the published work in significant ways, it may well end up being more highly cited, and that proper citation practice would be to cite both of these together. Some examples of the aspects that should be compared between the two papers are:*

*A1) The current manuscript contains an elegant demonstration of the mechanism of copy number gain via segmental duplication, which should be highlighted. The results described in the first three subsections of the Results section, on the phylogenetic origin and the association of increased copy number with increased body size provide independent added value that goes beyond the Schiffman.*

*A2) Some of these results on RTG expression are more precise than those reported in the Schiffman et al. paper. The authors need to go over the supplementary material as well as the results in the published paper and point out where they agree, where they do not, and where these results extend the results from Schiffman et al. For example, using RNA-seq, the authors show that the retrogene RTG12 is the variant most predominantly transcribed in elephant cells. In contrast, Schiffman et al. employed RT-PCR to document expression of \'retrogenes\'. How many of the retrogenes are actually expressed? Is it possible that retrogenes are expressed in a cell type-specific manner (e.g. fibroblasts in this paper versus lymphoblastoids in Schiffman\'s paper?).*

We apologize for not explicitly addressing the Abegglen et al. (2015) study in our prior submission, although we were aware of their manuscript was forthcoming we did not have access to it prior to our submission to *eLife* (it was published a few days after our submission).

In our revised submission we have dedicated a section of the Discussion ('Comparison to previous studies of elephant TP53') to specifically compare and contrast our findings to those of Abegglen et al. (2015). While we compare our results to Abegglen et al. (2015) in detail in the revised Discussion, our key observations are that: 1) Abegglen et al. (2015) did not determine the mechanisms of expansion whereas we have, therefore we have elaborated our discussion of the mechanisms of duplication; 2) Abegglen et al. (2015) found that elephant and human cells had different sensitivities to ionizing radiation, but their taxon sampling did not allow for polarizing which species was different whereas our explicit phylogenetic approach allows us to determine that elephants evolved increased sensitivity to DNA-damage; and 3) Abegglen et al. (2015) used RT-PCR and Sanger sequencing to show two distinct transcripts were expressed in elephant PBMCs, but they did not assign the loci to which these transcripts correspond. We analyzed the chromatograms shown in Abegglen et al. eFigure 4 and found that the 185bp product is a transcript from the TP553RTG14 gene and the 201bp product is a transcript from the TP553RTG5 gene. Thus, our combined data suggest that at least five TP53RTG genes are transcribed. Furthermore, we did not observe TP553RTG14 or TP553RTG5 expression in adipose, placenta, or fibroblasts suggesting that the expression of some TP53RTG genes is tissue-specific.

*B) Unclear mechanism of action of the retrogene-encoded p53 variants. The two papers disagree on the mechanism of action of the retrogene-encoded proteins. Here, the authors describe a \'transdominant\' effect that does not involve MDM2 binding. In contrast, the work by Schiffman et al. concludes that the retroproteins do bind to MDM2. The data from both papers is weak in this regard. If RTG12 does not bind to MDM2 as indicated in this paper, how is then its expression controlled upon DNA damage? What is the mechanism by which UVC leads to significantly more expression of RTG12? To address this issue, the authors should test whether RTG12 induction is at the level of RNA or protein stability, and to define whether Nutlin (an inhibitor of the MDM2-p53 interaction) also induces protein accumulation in this setting. Furthermore, their current model does not include stabilization of RTG12 protein upon DNA damage.*

We have greatly expanded our revised manuscript and now dedicate a section of Results, a figure ([Figure 10](#fig10){ref-type="fig"}), and a section of the Discussion to comparing our model to the Abegglen et al. (2015) model and specifically test our model and theirs. While those analyses are too complicated to include here, we show that: 1) Abegglen et al. (2015) actually do not demonstrate an interaction between TP53RTG9 and MDM2, the co-IP shown in their eFigure 5C *does not* have a band at the size expected for MDM2 (eFigure 5C, top panel). It is unclear to us why they conclude there MDM2 co-IP'd with TP53RTG9; 2) A tryptophan residue in TP53 critical for the interaction between TP53 and MDM2 is substituted for glycine in all TP53RTG proteins; 3) This W-\>G mutation is predicted to severely destabilize the TP53RTG/MDM2 interaction; and 4) TP53RTG12 does not co-IP with MDM2. Thus we conclude that the Abegglen et al. (2015) model of TP53RTG proteins acting as decoys for the MDM complex is unlikely.

In contrast we show that: 1) The TP53 dimerization domain in TP53RTG proteins is conserved; 2) A model of the TP53/TP53RTG12 dimer is nearly indistinguishable from the TP53/TP53 dimer; and 3) TP53RTG12 co-IPs with TP53. Based on these data we propose a model in which TP53RTG proteins dimerize with TP53, thereby protecting TP53 from the MDM complex because the MDM complex only (efficiently) binds to TP53 tetramers. We have yet to demonstrate how TP53 is released from the protection of TP53RTG proteins, clearly this is an important part of our model but given the scope of the current paper believe this is best left to a follow up paper.

We note, however, that we do not provide evidence that TP53RTG expression is increased upon UVC exposure. Our Western blot demonstrating bands at the expected size for TP53RTG12 (and TP53RTG19) is of total protein from cells treated with UVC and the proteasome inhibitor MG132. The goal of this experiment was to ascertain if there was evidence for TP53RTG proteins, not their regulation by DNA-damage. Thus we sought to stabilize TP53 and prevent its degradation, so that we might accumulate and potentially observe low abundance proteins. We agree that it is important to demonstrate how TP53RTG expression levels are affected by DNA damage, and if this is mechanism that releases TP53 from TP53RTG dimerization.

*How does RTG12 in this manuscript compare to RTG9 in the paper by Schiffman et al? Could it be that differences in putative binding to MDM2 among the two papers are due to sequence variations in the N-terminus domain of the various retroproteins? To address this, the reviewers request a figure showing aminoacid and nucleotide alignments of the N-terminus transactivation domain regions for all RTGs, highlighting the residues known to be important for transactivation and binding to MDM2, and including all proper Genbank identifiers for each sequence. One of the reviewers pointed out that the MDM2 binding site is mutated in all the TP53RTG proteins (for those that initiate at the first ATG). Furthermore, the same Reviewer observed that, from analysis of the sequences available in Genbank, all the TP53RTGs except one can produce a protein of at least 79 amino-acids, as some TP53RTG can be translated from codon 728 or 940. This should be discussed in the revised manuscript.*

We have compared the sequence of RTG9 from Abegglen et al. (2015) to our TP53RTG12 and conclude they are the same protein (100% protein and nucleotide identity). Thus based on our revised analyses of MDM2 binding by TP53RTG proteins, including the observation that the MDM2 biding site is mutated in all TP53RTG proteins (we thank the reviewer for this very helpful observation), we conclude that the Abegglen et al. (2015) model is not supported by current data. We now include a panel in [Figure 9](#fig9){ref-type="fig"} showing the location of functional domains in TP53 and TP53RTG proteins, and logos of the MDM2 interaction motif and TP53 dimerization motif in TP53 and TP53RTG proteins to highly conserved and divergent residues, and a table that includes Ensembl IDs for all TP53RTG genes. We also briefly discussed alternative start sites for TP53RTG proteins in our conclusion section.

*To further support their \'transdominant\' mechanism, the authors should simply perform co-immunoprecipitation of full-length p53 protein using the C-terminal p53-specific 421 monoclonal antibody (the epitope is conserved in the elephant p53 protein). The 421 antibody will not bind to TP53RTG proteins, which lack the 421 epitope. Thus, the co-immunoprecipitation of TP53RTG proteins with full-length elephant p53 protein will unequivocally prove the formation of a protein complex with full-length p53.*

This was a great suggestion and we worked for very many months to optimize our co-IP and Westerns with the 421 antibody, however, we have been unable to demonstrate that the 421 antibody recognizes the elephant TP53 protein. While this experiment would have been very informative, we have nonetheless demonstrated the formation of a protein complex with full-length human TP53 and Myc-tagged TP53RTG ([Figure 10J](#fig10){ref-type="fig"}) in support of our transdominant model.

*Finally, the authors propose that the TP53RTG proteins inhibit tetramerization of p53. However, tetramerization of p53 is absolutely required for p53 transcriptional activity. In addition, MG132 seems to induce ubiquitination of p53 in elephant cells treated with DNA-damaging agents despite expression of TP53RTG12. Therefore, the model involving inhibition of tetramerization and ubiquitination is not possible. Altogether, the experiments proposed here will enable the authors to produce a more accurate model of p53 regulation by the p53 retroproteins in elephant cells.*

MG132 does not induce ubiquitination of TP53 in elephant cells treated with DNA-damaging agents despite expression of TP53RTG12, rather MG132 prevents the proteasome from degrading ubiquitinated proteins leading to their accumulation. Therefore, this experiment cannot be used to determine if TP53RTG proteins protect TP53 from ubiquitination. We have edited the text to clarify this point.

As the editors and reviewers can imagine, we are very eager to test our 'guardian' hypothesis and are currently developing an in vitro ubiquitination assay that will allow us to test if TP53RTG proteins protect TP53 from MDM2-mediated ubiquitination. While this hypothesis is a key part of our model, a full test is beyond the scope of the current manuscript. We now provide data indicating DNA damaging agents cause a rapid and extreme decrease in TP53RTG transcripts, suggesting down-regulation of TP53RTGs upon DNA damage allows for tetramerization of TP53 and the initiation of TP53 signaling.

*C) Concern about the use overexpression experiments and HEK293 cells. Reviewers were concerned about the use of ectopic overexpression of TP53RTG12 in mouse cells and human HEK293 cells. The observed phenotypes (e.g. hypersensitivity to DNA damage) could be due to artifact-prone overexpression analysis. In addition, it is well established that p53 is inactivated and stabilized by a viral transforming protein in HEK293 cells. Therefore, the value of the MDM2 experiments conducted in HEK293 cells is unclear. In order to unequivocally demonstrate that TP53RTGs regulate the p53-dependent cellular response to DNA damage, the authors must knockdown endogenous TP53RTG expression using TP53RTG-specific siRNAs in elephant cells. Since the authors have identified long nucleotide sequences unique to TP53RTG mRNAs, it is then possible to design siRNAs that will reduce TP53RTG expression without affecting TP53 expression in elephant cells. It will be possible then for the authors to test their hypothesis in elephant cells. Furthermore, transfection of TP53RTG siRNA would enable the authors to unequivocally identify the protein bands corresponding to TP53RTG proteins via Western blot.*

We agree that the most convincing demonstration of the functional importance of TP53RTG genes would be to knockdown or knockout their TP53RTG expression. We tried to knockdown expression with numerous TP53RTG-specific siRNAs targeting different regions of the TP53RTG transcripts before our initial submission. While these experiments were able to knockdown TP53RTG expression they always cross-reacted with TP53 leading to reduced TP53 expression as well.

Fortunately, we have recently identified a pan TP53RTG siRNA that reduces TP53RTG expression \~70% and does not cross react with TP53. To test if TP53RTGs are functional we used this siRNA to knockdown TP53RTG transcripts and assayed induction of the TP53 signaling pathway in response to DNA damage and MDM2 antagonism. We show that knockdown of TP53RTGs in untreated cells increased baseline TP53 signaling, consistent with our 'Guardian' model, and also reduced TP53 signal after treatment with DNA damage inducing agents and Nutlin-3a. These data suggest that TP53RTG proteins have two distinct functions, inhibiting TP53 signaling in the absence of inductive signals and potentiation of TP53 signaling after induction of DNA damage.

*D) Interpretation of the various \'protein bands\' observed in elephant cells. In addition to the siRNA experiments mentioned above, reviewers pointed out that the authors cannot accurately identify and name the p53 isoforms observed in their electrophoresis experiments. The elephant p53 protein has no methionine at codon133 and p53psy has not been demonstrated in elephant cells. Furthermore, the bands above 50kD may be polymers or ubiquitinated p53 proteins or cross-reacting bands. Thus, it is essential to define the identity of these bands with TP53 siRNAs (the C-terminal region would provide ample sequence space to design these siRNAs). Also, the protein molecular weight marker is not displayed in any of the immunoblots, which prevents proper interpretation of these results.*

We agree that the data supporting translation of one or more TP53RTG genes is circumstantial and that the Western blot shown in [Figure 5E](#fig5){ref-type="fig"} is far from conclusive. We note that we do not conclude from this blot that TP53RTGs are translated, rather we conclude that we "identified an elephant-specific band at the expected size for the TP53RTG12 (19.6kDa) and TP53RTG19 (22.3kDa) proteins, suggesting that the *TP53RTG12* and *TP53RTG19* transcripts are translated in elephant fibroblasts" and explicitly state we identified "high molecular weight bands corresponding to previously reported SDS denaturation resistant TP53 oligomers (Cohen et al., 2008; Ottaggio et al., 2000) and (poly)ubiquitinated TP53 conjugates (Sparks et al., 2013)".

Unfortunately identifying an antibody, particularly a monoclonal, that recognizes elephant TP53 and TP53RTGs has been remarkably difficult. However, our observation that knockdown of TP53RTGs and over-expression of TP53RTG12 in mouse cells has functional consequences on TP53 signaling and the induction of apoptosis provides further support that TP53RTG is translated and functional.

*E) Incomplete discussion of the impact of p53 copy number gain in organismal biology, tumor suppression and ageing/senescence. The p53 literature abounds with studies exploring the impact of additional copies of the p53 gene, including \'retrogenes\'. The reviewers concluded that this manuscript would be much improved by a thorough discussion of these studies. For example, the authors should discuss the p53 pseudogenes in mouse and rat, which are expressed and seem to compromise the activity of functional p53. Importantly, it is well established that an extra copy of full-length p53 in mice leads to hyperactive apoptotic activity, shortening the lifespan of the organism and also inducing neurodegenerative diseases. Thus, the authors should discuss the \'super p53\' mouse models (García-Cao et al., EMBO J 2002; Tyner et al., Nature 2002; Maier et al. Genes and Dev 2004).*

*Another important point in this area is that the authors have not discussed the fact that TP53RTG12 seems to be the only highly expressed p53 pseudogene in elephant cells. How could the authors conclude that the low cancer incidence in elephants is due to the \'multiple copies\' of p53 pseudogenes, while the effects of all TP53RTGs seem to be driven by a single retrogene, TP53RTG12? In fact, the authors show that all the TP53RTGs are expressed in the RNA seq data -although at very variable levels-, and they should emphasize this observation; otherwise the story does not reconcile with the existence of two expressed p53 pseudogenes in rat and the two or single expressed p53 pseudogenes in mouse (Tanooka et al., Cancer Res. 1998 and Gene 2001). The authors made a very important discovery, as elephant species may have evolved a molecular mechanism to uncouple the tumor suppressive activity of p53 from its pro-ageing activity. Therefore, the authors should elaborate on whether it is the number of RTGs and/or the tissue specific expression of RTGs and/or the type of RTG (i.e. as defined by the amino-acid sequence of the RTG) that fine tunes p53 activities toward enhanced tumor suppression without hyper-reactivity to cellular stress.*

We have completely rewritten the Discussion to explicitly address the potential functional consequences of the TP53RTG genes on organismal biology, tumor suppression, and ageing/senescence. For example, we discuss in detail transgenic mouse models with extra copies of TP53, including the 'super p53' mice, with respect to potential trade-offs with traits such as premature aging and accelerated reproductive senescence. We also suggest that elephants may have avoided these costs because functional TP53RTG genes likely evolved through non-functional intermediates, which accumulated loss of function mutations that minimized redundancy with TP53.

As we discuss in greater detail above, our data combined with the data published in Abegglen et al. suggest that at least five TP53RTG genes are transcribed, many of which are likely-tissue specific. However, we did not mean to imply that all, or even most TP53RTGs are expressed and function. Indeed, we suspect that many are non-functional pseudogenes generated by a simple birth-and-death process in which the birth rate exceeds the death rate leading the neutral accumulation of TP53RTG pseudogenes. This process can be expected to "snowball" leading to the rapid accumulation of pseudogenes. To address this concern we have added a section to the Discussion ('An embarrassment of riches?') in which is explicitly state that we expect only a subset of TP53RTG genes will be functional at any point in the evolution of elephants and that the gene family is likely evolving by a birth and death process.

With respect to potential expressed or functional TP53 pseudogenes in mouse and rat, we have extensively surveyed the literature including Tanooka et al. (1998) and Tanooka et al. (2001) and cannot find evidence that Muroid TP53 pseudogenes are expressed. Tanooka et al. (1998), for example, report the formation of a chimera between TP53 and a TP53 pseudogene in mice that arises because of homologous recombination after repeated local β-irradiation. The recombination occurred near the 5\' end of exon 5 leading to a 5-bp deletion in exon 6 of the expressed TP53 allele. A follow up study reports the generation of transgenic mice carrying a mutant version of this TP53 (mp53) allele, but neither study provides evidence that the pseudogene is expressed. Similarly, Tanooka et al. (2001) report the identification of the TP53 pseudogene in multiple populations and species of mice but do not provide evidence that these pseudogenes are expressed. We have identified several papers describing TP53 pseudogenes in mouse and rat (Ciotta et al., 1995; Czosnek et al., 1984; Hulla, 1992; Tanooka et al., 1995; Weghorst et al., 1995; Zakut-Houri et al., 1983), but none report expression data. Thus we conclude there is little direct evidence that TP53 pseudogenes are expressed in mouse and rat.
